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The treatment regimen for patients that present with glioblastoma (GBM) has improved 
over the years with the advent of the chemotherapeutic Temodar® and the inclusion of 
concurrent radiotherapy. However, the 5 year survival rate remains below 10% [1]. The 
current treatment regimen is unable to effectively eradicate all pathological tumor cells 
that can reside up to centimeters away from the tumor bulk. This leads to tumor 
recurrence, the main culprit behind the disease’s low survival rate. In addition, currently 
developed conventional therapies fail to address this need for improved therapeutic 
distribution in order to achieve therapeutic outcome. In this thesis, we develop 3 different 
nanotechnology platforms that are engineered to distribute throughout the brain and 
tumor microenvironment upon intracranial administration using an optimized form of 
convection enhanced delivery (CED). It is my belief that this technology represents a 
promising start towards addressing the poor survival rates and quality of life of those 
patients suffering from GBM. 
 We began by tailoring the parameters that allow for effective administration of 
therapeutics using CED. Following the size and surface chemistry criteria established by 
our recent Science Translational Medicine publication (sub-100nm, near neutral surface 
charge) [2], we demonstrate that a probe, brain penetrating nanoparticle (NP) can achieve 
synergistically improved distribution in the brain of both mice and rats when delivered 
using CED. Furthermore, a mechanistic investigation of the parameters of CED reveals a 
combination strategy (i.e. hyperosmolar infusate solution + brain penetrating NP) that can 
enable more homogeneous therapeutic distribution in the brain, which is currently the 
main obstacle in successful translation of CED-based therapies to the clinic. 
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With the understanding gained from these probe NPs, we developed three 
therapeutic brain penetrating NP formulations with dense surface coatings of 
polyethylene glycol (PEG) that are capable of delivering chemotherapeutics or 
therapeutic gene sequences. When administered using CED, these therapeutic NPs 
similarly achieve widespread distribution in the brain. The first platform is a 
biodegradable poly(lactic-co-glycolic acid)(PLGA) polymer and we demonstrate its 
ability to rapidly penetrate and distribute in the brain tissue as compared to gold standard 
NPs that have been engineered to pass through the blood brain barrier (BBB). Secondly, 
we developed a non-viral brain penetrating gene vector platform derived from a highly 
efficient polyethylenimine (PEI) polymer. When administered using CED, they 
successfully deliver higher overall levels of widespread reporter gene expression. These 
NPs can be rapidly adopted to deliver therapeutic plasmids that can encode for p53 for 
anti-tumoral efficacy or glial derived neurotrophic factor (GDNF) for treatment of 
Parkinson’s disease. Finally, we’ve engineered brain penetrating cisplatin NPs that, when 
administered using CED, leads to curative effects in a clinically relevant, orthotopic 
rodent model of human GBM.   
Together, these three brain penetrating NP formulations, in conjunction with 
optimized CED administration, represent promising adjuvant therapies to be tested for 
treatment of GBM. 
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The diffuse nature of many neurological diseases necessitates the development of novel 
treatments (i.e. nanotechnology) that can similarly distribute throughout the central 
nervous system (CNS) to target pathological abnormalities. To do so, these therapies 
must be aptly engineered to enable their unhindered distribution throughout the brain 
interstitium upon administration. Using probe polystyrene nanoparticles (NP), our lab has 
previously shown that in order for NPs to rapidly penetrate and travel through the brain 
extracellular spaces, they must be designed to be small (sub-100 nm) and non-adhesive 
(dense surface layer of polyethylene glycol (PEG)). In this thesis, we build upon our prior 
findings by developing several therapeutic, brain penetrating NP platforms for the 
treatment of human glioblastoma (GBM) and intracranially administer them into the 
brain using convection enhanced delivery (CED), a common method of adminstration 
that has demonstrated promise in human clinical trials.  
 Chapter 2 of this thesis describes the current background and problems facing the 
acceptance and implementation of new nanotechnology treatments for GBM. Chapter 3 
begins to address those shortcomings by establishing that a sub-100 nm, densely PEG 
shielded NP can safely achieve widespread distribution upon CED administration into the 
healthy rodent brain. We find that this improved distribution is observed completely 
independent of NP concentration. Furthermore, we demonstrate that the fate of the 
infused NPs remain distinct as non-adhesive NPs are likely uptaken and cleared through 
unactivated microglia whereas unmodified NPs remain entrapped within the brain 




 Having conducted the majority of prior studies using probe, polystyrene NPs that 
are incapable of delivering therapeutic agents, we further engineered brain penetrating 
NPs derived from biodegradable poly(lactic-co-glycolic acid)(PLGA), an FDA approved 
polymer that has been widely utilized in drug delivery applications [3]. Chapter 4 focuses 
on testing PLGA NPs that possess a wide variety of surface-altering surfactants that have 
previously been shown to enable NP transcytosis across the BBB. We compare the ability 
of our NP formulations to diffuse throughout healthy brain tissue to the gold-standard 
human serum albumin NPs (HSA-NP) that are designed for passage through the BBB. 
Intriguingly, we find that surfactants that enable BBB passage are poor for NP diffusion 
within the brain interstitium. In fact, we confirm that cholic acid (CHA), is an ideal small 
molecule surfactant that enables densely PEGylated PLGA NPs to diffuse 2500 times 
faster in brain tissue than HSA-NP. When administered in vivo using CED, these PEG-
PLGA NPs coated with CHA achieve widespread distribution in the rodent striatum, 
mirroring our findings in Chapter 3. 
 In Chapter 5, we focus on developing a non-viral, brain penetrating gene vector 
platform, given that the field of gene delivery has gained momentum as a promising 
approach for treatment of mutation-based diseases such as GBM. We utilize 
polyethylenimine, the gold-standard polymer choice for synthesis of non-viral gene 
vectors and highly PEGylate the linear chain to achieve a densely PEGylated NP upon its 
complexation with plasmid DNA. In comparison to conventionally PEGylated NPs (3-
fold less PEG), our gene vectors are able to rapidly diffuse in brain tissue and achieve 
widespread distribution when administered using CED, similar to what we observed in 




higher and 2) more widespread levels of transgene expression. Thus, this has set the 
groundwork for transitioning to delivering therapeutically relevant anti-tumor genes such 
as p53 or thymidine kinase. 
Although gene therapy has demonstrated promise in preclinical studies, 
chemotherapeutics such as temozolomide (TMZ) remain the standard of care for GBM 
[4]. However, TMZ and many chemotherapeutics continue to suffer from lack of efficacy 
and increased toxicities. In Chapter 6, we develop a highly cytotoxic, cisplatin (CDDP) 
brain penetrating NP for the treatment of rodents bearing GBM tumors. We engineered 
sub-100 nm, CDDP NPs with a near neutral surface charge that widely distributes in 
brain tissue following CED. These NPs exhibit 24 hour controlled release of the CDDP 
payload, thereby significantly improving the therapeutic index as compared to freely 
administered CDDP. Most importantly, when rodents bearing malignant glioma are 
treated with this CED-administered CDDP NP, 80% of the animals are cured (i.e long 
term survival and no tumor regrowth). Thus, this CDDP platform represents a promising 
adjuvant therapy for human GBM following tumor resection. 
 Although our combination of CED + brain penetrating NPs in Chapters 3-6 have 
all demonstrated very promising preclinical results, many clinical trials utilizing CED as 
the main administration method have ultimately failed [5, 6]. The inability to meet 
primary and second endpoints have been attributed to nonhomogeneous distribution of 
the infused therapeutic; namely, therapeutic accumulation in perivascular spaces (PVS) 
has been shown to occur [7, 8] which ultimately prevents the therapeutic from targeting 
the pathological cells in the brain interstitium. Chapter 7 looks to address these 




thereby modulating the tissue microenvironment to prevent therapeutic sequestration and 
enhance the distribution of NPs in the brain. Furthermore, we find that these NPs are able 
to travel through PVS to far distances (up to 1.5 mm) and escape back into the brain 
interstitium. We believe this combination delivery strategy may be a promising approach 
to addressing the current limitations of CED-based therapies in clinical trials. 
 Altogether, we have built upon our lab’s previous findings by 1) developing three 
therapeutic brain penetrating NP formulations and 2) optimizing their intracranial 
delivery through a mechanistic investigation of CED as the administration strategy. These 
results corroborate our prior findings that a NP must be engineered with a dense PEG 
layer in order to achieve penetration and widespread distribution within the brain 
interstitium. Here, we’ve engineered multiple tailorable platforms capable of delivering 
therapeutic genes or chemotherapeutics. We believe that these NPs may be of the utmost 
interest, especially given the burgeoning field of gene delivery along with the ongoing 








2.1. Glioblastoma and nanotechnology treatments 
Central nervous system (CNS) diseases such as malignant brain gliomas remain very 
difficult to treat due to the infiltrative, malignant nature of the disease [9]. In the case of 
GBM, the current treatment regimen involves surgical resection followed by concurrent 
irradiation and chemotherapy, but the median survival time of GBM patients remains 
approximately 16 months [4]. This poor prognosis stems from tumor relapse due to 
residual tumor cells following treatment [9-12]. The chemotherapeutic of choice for 
newly diagnosed GBM, Temodar ® (Temozolomide, TMZ), is orally administered but 
despite its lipophilic makeup and ability to cross the blood brain barrier (BBB), patient 
survival time was only slightly improved [4, 13]. TMZ is still limited in its efficacy due 
to its inability to sufficiently accumulate in the CNS and fully eliminate residual 
infiltrative tumor cells. Furthermore, TMZ is highly restricted by its dose limiting 
systemic toxicities of myelosuppression and lymphopenia [14-16]. Nanotechnology 
based therapeutics are a promising strategy to more effectively target and treat these 
residual tumor cells but they must be engineered to effectively overcome multiple hurdles 
including the brain tissue barrier to achieve enhanced therapeutic distribution within the 
tumor.  
 
2.2. Barriers to effective therapeutic NP delivery to the brain 
Two main barriers exist to prevent effective delivery of therapeutics to the brain; the 
blood brain barrier (BBB) is the first hurdle that systemically administered nanocarriers 




Passive passage through the BBB requires the molecules to be lipophilic and less than 
500 Daltons in size [18]. Therefore, most NPs are effectively barred from entering the 
brain through the systemic route. Several strategies have been developed to transiently 
disrupt or bypass the BBB [19-21]; however, the dose of therapeutic that is achieved in 
the brain following this delivery method remains low. Thus, direct intratumoral 
administration of the therapeutic remains the most promising in being able to achieve 
high concentrations of the therapeutic within the local tumor bulk. If the nanocarrier is 
able to overcome or bypass the BBB, the brain tissue barrier (BTB) serves as a second 
obstacle to effective therapeutic delivery. The BTB is composed of the nanoporous and 
highly adhesive brain extracellular matrix (ECM) that sterically or adhesively traps 
therapeutic NPs upon their entry into the brain parenchyma [2, 22, 23]. In addition, tumor 
microenvironments often possess increased cellular density and upregulated proteoglycan 
concentrations, both of which further prevent therapeutic NPs from reaching the target 
cells [24]. 
To address the limitations of nanotechnology delivery to overcome the BTB, two 
strategies have recently been developed: 1) effectively engineer a NP to minimize the 
interactions that entrap the NP and 2) utilize improved delivery methods such as CED to 
drive the therapeutic to overcome those hindering interactions. 
 
2.3. Strategy 1: Optimized nanocarriers for brain delivery 
In both preclinical and clinical studies, intracranial infusion of nanocarriers leads to 
suboptimal distributions if the nanocarrier characteristics are poorly considered [25, 26]. 




optimal NP characteristics for brain penetration to comprise a small size (<100 nm in 
diameter) and a near neutral surface chemistry to minimize adhesive interactions with the 
brain ECM [2, 20]. When our lab synthesized these “brain penetrating” NPs in this 
fashion, we demonstrated that these NPs can rapidly diffuse within the brain parenchyma 
to achieve higher distribution [2] and prolong survival of orthotopically implanted, 
glioma-bearing rodents [27]. These parameters have been further corroborated by high 
impact publications that have intracranially delivered therapeutic “brain penetrating” 
drug and gene nanocarriers and have achieved significant improvement in survival of 
tumor-bearing rodents [28, 29]. Thus, although the need to overcome the BTB has long 
been overlooked in comparison to the BBB, addressing the BTB through the tailoring of 
NP physicochemical characteristics has slowly gained attention as an essential step 
towards effective therapeutic delivery to the brain. 
 
2.4. Strategy 2: Local delivery – Convection enhanced delivery 
Local administration of chemotherapeutics, such as implantation of the carmustine-
loaded Gliadel® wafer, has demonstrated promising results as an adjuvant therapy [30] 
by circumventing the BBB, reducing potential systemic toxicities, and increasing 
concentration of drug in the tumor [31]. However, topically administered therapeutics 
suffer from decreased penetration into the tumor parenchyma and rapid clearance from 
the extracellular space, thereby limiting the overall benefits [31, 32]. Simultaneously, 
other researchers have employed convection enhanced delivery (CED) as an alternative 




even with CED, poorly designed NPs are unable to distribute in the brain which leads to 
poor efficacy of the treatment [26, 33].  
CED of therapeutics has shown promise in preclinical studies for improving 
therapeutic distribution in the brain parenchyma but its clinical success has been largely 
limited. A number of recently completed or ongoing clinical trials focused on combatting 
the diffuse pathology of malignant gliomas or Parkinson’s disease currently deliver 
therapeutics into the brain using CED [5, 34]. Unfortunately, most of these trials have not 
met their primary endpoint which is hypothesized to be due to poor distribution of the 
therapeutic from the injection site, sequestration of therapeutic within perivascular 
spaces, lack of training and poor implementation of CED by surgeons, and failure to 
normalize the CED hardware across multiple institutions [8, 34]. As our understandings 
of CED grow as a result of improved real-time monitoring and imaging techniques [35], 
very promising preclinical results employing CED against malignant glioma have 
recently come to light [28, 29], yet their therapeutic of choice (viruses, PLGA paclitaxel) 
still face numerous obstacles prior to translation to clinical trials and into the clinic.  
Here, we hypothesize that the combination delivery of a brain penetrating NP 
platform using optimized CED parameters is a promising therapeutic modality for 





3. INTRACRANIAL ADMINISTRATION OF NON-ADHESIVE 




Convection enhanced delivery (CED) was first described in 1994 [36] as a strategy to 
drive therapeutics to farther distances within the brain interstitium using the bulk flow of 
a fluid. Even today, the fact that numerous clinical trials have or currently implement 
CED for treatment of Parkinson’s disease and recurrent malignant glioma continues to 
underscore the enthusiasm for this delivery method [5, 31]. This excitement stems from 
the fact that many brain diseases are characterized by the presence of pathological cells or 
abnormal extracellular structures that are highly disseminated throughout the brain tissue. 
Thus, NPs must be able to follow and target these widely distributed entities, which may 
theoretically be achieved through CED [20]. However, in practice, non-homogeneous 
distribution of the administered therapeutic occurs with high concentrations remaining 
near the catheter implantation site, confined within perivascular spaces, or localized 
within white matter tracts [7, 8, 25, 37]. Conventionally designed therapeutics, even 
when delivered via the bulk flow of CED, are often found associated with components of 
the brain extracellular matrix (ECM), which sterically and adhesively prevents infused 
therapeutics from effectively distributing throughout the brain. These challenges have led 
to a significant number of terminated CED-based clinical trials that have failed to meet 
their primary and secondary outcome measures likely due to suboptimal distribution of 
the therapeutic [8, 25, 38]. Indeed, very promising preclinical results have recently come 
to light which detail significant survival benefits in malignant glioma bearing rodents 




intracranially administered using CED [28, 29]. Therefore, optimizing and delivering a 
NP therapeutic that is able to achieve maximal distribution within the brain parenchyma 
may result in even further improvements in both preclinical and clinical investigations for 
CNS diseases. 
We have previously developed and demonstrated that a NP up to 114 nm in 
diameter, if shielded with a dense layer of polyethylene glycol (PEG), can minimize 
interactions with the brain ECM and rapidly diffuse through the intercellular spaces (ICS) 
in the brain parenchyma [2]. However, relying solely on diffusion to distribute 
therapeutic NP throughout the ICS achieves only sub-optimal therapeutic concentrations 
at farther distances [20]. Therefore, we hypothesize that the combined delivery of a non-
adhesive NP using CED may be a promising strategy to overcome the brain ECM and 
achieve therapeutically relevant distribution in the brain. 
 
3.2. Methods 
3.2.1. NP preparation and characterization 
Forty nm dark red fluorescent carboxylated polystyrene microspheres (PS-COOH) (Life 
Technologies, Grand Island, NY) were modified by conjugating a dense layer of 5 kDa 
methoxy-PEG-amine (Creative PEGworks, Winston Salem, NC), onto the surface, 
according to a previously published protocol [2], to obtain densely PEGylated 
polystyrene NPs (PS-PEG). NP size and surface chemistry were characterized in a 
standard 10 mM NaCl solution through dynamic light scattering and laser doppler 






3.2.2. In vivo CED of various nanocarriers 
When preparing NPs for intracranial CED, stock PS-PEG and PS-COOH were each 
diluted 25-fold in 0.9% saline and mixed at a 1:1 ratio for a final concentration of 1 
mg/mL. Additional NP concentrations were also investigated including final 
concentrations of 25 mg/mL and 0.1 mg/mL in normal saline.  
Female CF-1 mice weighing 20-30 g in mass or male Sprague Dawley rats 
weighing 300-400 g in mass were anesthetized with a mixture of ketamine (75 mg/kg) 
and xylazine (7.5 mg/kg). For mice, a 2 cm sagittal incision was made on the head and a 
burr hole was made 2 mm lateral to the bregma. All NP solutions or infusate solutions 
were loaded into a 50 L Hamilton Neurosyringe with a 33 gauge syringe and set with a 
1 mm step (Hamilton, Reno, NV). The syringe was vertically mounted on a Chemyx 
Nanojet Injector Module (Chemyx, Stafford, TX) which was held on a small animal 
stereotactic frame (Stoelting, Wood Dale, Il). The loaded syringe was lowered to a depth 
of 2.5 mm below the mouse dura and a total of 2 µL of the solution was administered 
over 10 minutes at a rate of 0.2 L/min. For rats, a burr hole was made 3 mm lateral to 
the bregma and a total solution of 20 L of solution was administered at a depth of 3.5 
mm at a rate of 0.33 L/min. In both rodents, the cannula was allowed to sit for 5 minutes 
following the completion of infusion and was then withdrawn at a rate of 1 mm/min. The 
animal was then sutured (Covidien, Mundelein, Il) and placed on a heating pad. 
We conducted a single CED administration into the ex vivo harvested brain of a 
female New Zealand rabbit. The animal was euthanized using an overdose of 




ex vivo. PS-PEG nanoparticles were administered at a concentration of 1 mg/mL at a rate 
of 0.33 uL/min for 90 minutes at the following coordinates: 23 mm posterior to the 
bregma, 3 mm lateral to midline, and 9 mm ventral. The thalamus was targeted given its 
high grey matter content, similar to the striatum in rodents. The brain was flash frozen 
and sliced/imaged for nanoparticle distribution. 
 
3.2.3. Tissue processing for NP imaging 
Animals were sacrificed 1 hour post-CED and the brains were fixed in formalin for 24 
hours and subsequently exposed to a 10%, 20%, and 30% sucrose gradient. The same 
procedure was followed for animals that were sacrificed 24 hours, 72 hours, and 7 days 
post-administration. Brains were mounted and cryosectioned at a thickness of 50 m 
(Leica Biosystems, Buffalo Grove, Il). Distances ± 1.5 mm from the injection site were 
carefully obtained. Slices were fixed with Dako fluorescence mounting medium (Dako, 
Carpinteria, CA) and imaged using a Zeiss confocal 710 laser scanning microscope 
(Zeiss, Jena, Germany) in the GFP and Cy5 channels at 5x magnification. The presence 
of background fluorescence was determined by comparing to the striatum of the 
contralateral hemisphere with no injection. Brain slice images were quantified for 
fluorescent distribution of PS-PEG or PS-COOH NPs by running the confocal laser 
scanning microscope images through a custom MATLAB script which thresholded the 
images at 10% of the maximum intensity (Fig S.4). Fluorescent distribution of NP in the 
ventricles or white matter tracts were avoided and not included in the quantification. The 
area of distribution calculated from each slice was multiplied by the slice thickness of 50 




lost during cryosection procedure, the area of distribution was taken as the average of the 
previous and following slices. Rarely was more than 1 slice lost from a brain specimen. 
Furthermore, to ensure that the observed volume of distribution (Vd) differences between 
the PS-COOH and PS-PEG NPs was not due to the use of GFP and Cy5 channels, we 
switched the fluorescent markers and confirmed that fluorescent PS-PEG NPs (Yellow-
green, GFP) exhibited significantly enhanced distribution as compared to PS-COOH NPs 
(Dark-red, Cy5). 
 
3.2.4. Staining of brain slices for specific cellular markers 
Tissues were harvested, post-fixed, and cryosliced at 10 m thickness. Tissues were 
mounted on glass slides, washed 3 times with PBS, and blocked with blocking buffer 
composed of 5% normal goat serum (Sigma Aldrich, St. Louis, MO) and 1% bovine 
serum albumin (Sigma Aldrich, St. Louis, MO) in PBS for 1 hour at room temperature. 
Tissue slices were incubated with primary rabbit anti-mouse Iba1 antibody (Abcam 
ab107159, Cambridge, MA), rabbit polyclonal anti-mouse NeuN (Millipore ABN78A4, 
Billerica, MA), or anti-glial fibrillary acidic protein (GFAP) (eBioscience, San Diego, 
CA) each diluted at 1:250 in blocking buffer for 16 hours at 4
o 
C. Tissues were washed 3 
times with PBS. For Iba-1 stain, tissues were further incubated with AF488 labeled goat 
anti-rabbit secondary antibody (Life Technologies, Grand Island, NY) diluted 1:500 in 
blocking buffer for 1 hour at room temperature. Tissues were washed 3 times with PBS, 
and then incubated with DAPI (Life Technologies, Grand Island, NY) at a 1:1000 




PBS and allowed to dry before mounting with Dako fluorescence mounting medium 
(Dako, Carpinteria, CA).  
 
3.2.5. Confocal imaging and MATLAB image-based processing 
Slices were fixed with Dako fluorescence mounting medium (Dako, Carpinteria, CA) and 
imaged using a Zeiss confocal 710 laser scanning microscope (Zeiss, Jena, Germany) in 
the GFP and Cy5 channels at 5x magnification. The presence of background fluorescence 
was determined by comparing to the striatum of the contralateral hemisphere with no 
injection. Brain slice images were quantified for fluorescent distribution of PS-PEG or 
PS-COOH NPs by running the confocal laser scanning microscope images through a 
custom MATLAB script which thresholded the images at 10% of the maximum intensity 
(Fig S.4). Fluorescent distribution of NP in the ventricles or white matter tracts were 
avoided and not included in the quantification. The area of distribution calculated from 
each slice was multiplied by the slice thickness of 50 m and summated across all images 
to obtain a total volume of distribution. If a slice was lost during cryosection procedure, 
the area of distribution was taken as the average of the previous and following slices. 
Rarely was more than 1 slice lost from a brain specimen. Furthermore, to ensure that the 
observed Vd differences between the PS-COOH and PS-PEG NPs was not due to the use 
of GFP and Cy5 channels, we switched the fluorescent markers and confirmed that 
fluorescent PS-PEG NPs (Yellow-green, GFP) exhibited significantly enhanced 




 To image for cell-specific markers, confocal images of stained slides were taken 
at high magnification (40x) for Iba-1 (microglia), NeuN (neurons), and GFAP 
(astrocytes). 
 
3.2.6. Statistical analysis 
Statistical testing between two groups were conducted using a two sample student t-test. 
If statistical comparisons involved more than two groups, testing was conducted with 
SPSS 18.0 software (IBM Inc.) using one-way ANOVA followed by Tukey honestly 
significant difference. Differences for t-test, ANOVA, and Tukey tests were considered 
statistically significant at p < 0.05. 
 
3.3. Results and Discussion 
3.3.1. NP characterization 
Fluorescently labeled 40 nm PS-COOH NP probes were modified with exceptionally 
dense surface PEG coatings according to our previously published protocol [2]. These 
densely PEGylated NP were approximately 60 nm with a near neutral surface charge (as 
indicated by 𝜁-potential), whereas unmodified, PS-COOH possessed a significantly 
anionic surface charge (Figure 3.1A). 
 
3.3.2. Surface chemistry of NPs affects volume of distribution 
Previous studies that have used CED to administer sub-100 nm, non-shielded NP fail to 
achieve significant NP distribution, likely due to adhesive interactions between the NP 




dense PEG coatings can rapidly diffuse in healthy and tumor rodent brain tissues, thereby 
leading to improved therapeutic outcome [2, 40]. Here, we discovered that the pressure-
driven flow provided by CED further improves the distribution of non-adhesive NP 
throughout the brain interstitium in both CF-1 mice and Sprague Dawley rats (Figure 
3.1B). Following infusion at a NP concentration of 1 mg/mL, the volume of distribution 
(Vd) of non-adhesive NP was consistently higher (~6-7 fold) than that of unmodified PS-
COOH in both species (Figure 3.1B, C).  We conclude that even the continuous pressure-
driven flow provided by CED cannot adequately overcome the adhesive interactions that 
occur between conventional NP (i.e. PS-COOH) and the brain ECM. Thus, a well-coated, 
non-adhesive NP surface is essential towards achieving significant distribution of NP 
away from the point of administration following CED. 
Given that we observed a scalable increase in the Vd of our PS-PEG NPs when 
increasing the volume of infusion from 2 L (in mice) to 20 L (in rats), we believe that 
further improvements in the Vd may be realized in larger animals that can tolerate larger 
volume of infusions. Indeed, in our single administration in a New Zealand rabbit, we 
found that a 30 L administration yielded a significantly higher than expected Vd of 110 
mm
3
. But given that this study currently consists of 1 specimen which was conducted in 
an ex vivo setting, further investigations with this animal model must be undertaken. 
Furthermore, this author acknowledges that the anatomical differences present in the 
brain of larger mammalian species (i.e. non-human primates and/or humans) would 
require careful placement of catheters and further adjustment of infusion parameters, as 





3.3.3. Concentration-dependent NP distribution 
In an attempt to address the limited NP distribution, several groups have administered 
high concentrations of small, conventional NP that saturate the available binding domains 
throughout the ECM, thereby enabling residual NP to distribute away from the point of 
infusion [26, 33, 43]. We therefore sought to determine the correlation between Vd of NP 
and infused NP concentration. When PS-PEG and PS-COOH were coinfused at 0.1 
mg/mL, 1 mg/mL, and 25 mg/mL, Vd of PS-PEG was 10.7-fold, 3.6-fold, and 1.3-fold 
higher than that of PS-COOH, respectively (Figure 3.3A). Importantly, the Vd of PS-
COOH increased with increasing concentrations of infused NP whereas PS-PEG 
achieved high Vd independent of concentration (Figure 3.3A, B). 
 
3.3.4. Cell specific uptake of NPs following intracranial infusion 
To mechanistically understand the fate of NPs following their infusion into the brain 
striatum, we imaged for the presence of PS-PEG and PS-COOH at 24 hours, 72 hours, 
and 7 days post-administration. At each timepoint, we found that the Vd of both PS-PEG 
and PS-COOH were qualitatively similar to their respective Vd at 1 hour post-CED 
(Figure 3.3A). Additionally, the PS-PEG fluorescence appeared significantly punctated, 
indicating accumulation of the NPs at specific locations within the striatum whereas PS-
COOH remained confined near the point of administration (Figure 3.4A). 
 Given that the appearance PS-PEG NPs at longer timepoints demonstrated cell-
specific accumulation, we further investigated the cell-specific uptake of PS-PEG and 
PS-COOH NPs at high magnification at a timepoint of 24 hours after CED 
administration. Qualitative images of individual cellular stains (Figure 3.4B) depict 




colocalization was observed with neurons and astrocytes. Of note, the microglia exhibit a 
ramified phenotype, indicating that they remain unactivated, as opposed to the pro-
inflammatory activated status indicated by an amoeboid morphology that may induce 
further injury [44]. Furthermore, PS-COOH NPs did not associate with any specific cell 
marker and instead, remain entrapped near the point of administration. Therefore, we 
hypothesize that a biodegradable NP that is engineered to be brain penetrating similar to 
our PS-PEG NPs may be safely administered, uptaken, and degraded/cleared by 
microglia, whereas a conventional NP may remain within the brain interstitium for longer 




We establish that non-adhesive NP, when administered using CED, can overcome the 
brain ECM and achieve significant distributions within the rodent brain interstitium, even 
when administered at low concentrations. Furthermore, the non-adhesive nature of these 
NPs enable them to be safely uptaken and cleared from the brain intercellular spaces into 
microglia. On the other hand, conventional NP remain entrapped near the point of 
administration and can only overcome the brain ECM following CED if they are 
administered at extremely high NP concentrations (Figure 3.2A, B), which may not be 






Figure 3.1: In vivo administration of PS-PEG and PS-COOH. (A) Physicochemical 
characterization of model polystyrene based nanoparticles. (B) Nanoparticle volume of 
distributions in CF-1 mouse and Sprague Dawley rats. (C) Representative 3D 
nanoparticle distribution volumes injected into rodent striatum. Images are overlayed on 






Figure 3.2: In vivo nanoparticle distribution in mouse, rat, and rabbit. (A, B, C) Qualitative coronal 
slice images depicting the area of distributions of PS-PEG nanoparticles (red) in (A) mouse, (B) rat, and 
(C) rabbit. (D) Quantitative volume of distribution (Vd) following 2 uL (mouse), 20 uL (rat), and 30 uL 
(rabbit) injections of PS-PEG nanoparticles. N ≥ 3 for mouse and rat quantitative calculations. N = 1 for 





Figure 3.3: Volume of distribution dependence on particle concentration. (A) 
Quantitative volume of distributions of PS-PEG and PS-COOH nanoparticles in relation 
to the concentration of particles administered. Statistical significance denoted by * P < 
0.05. (B) 3D reconstruction of PS-PEG (red) and PS-COOH (green) nanoparticles in the 







Figure 3.4: Time dependent uptake/clearance of nanoparticles in the brain. (A) 
Presence of PS-PEG (red) and PS-COOH (green) nanoparticles in the striatum at 
specific timepoints following CED infusion. Scale bar = 1mm. (B) Cell specific 
staining for microglia, neurons, and astrocytes depict uptake of PS-PEG 







4. DEVELOPMENT OF BIODEGRADABLE BRAIN-PENETRATING 




The development of therapeutic-loaded NPs represents a promising strategy to 
deliver drugs into the brain for the treatment of primary brain tumors such as GBM. 
Furthermore, many of these NP platforms are now engineered from biocompatible 
polymers that can readily degrade in the physiological microenvironment, effectively 
delivering the target payload without negatively impacting the normal functioning of 
surrounding healthy tissue [45]. Given that efforts on therapeutic delivery to the brain has 
primarily focused on overcoming the BBB, the majority of these biodegradable NPs have 
been engineered to solely address the specific criteria to enable NP entrance into the brain 
from systemic circulation. However, the presence of the BTB has only been recently 
elucidated, which has led to the subsequent emphasis that in order to achieve effective 
therapeutic delivery to the brain, therapeutic, biodegradable NPs must also be similarly 
engineered to overcome this hurdle [2, 22].  
NP delivery to tumors has focused on both passive (enhanced permeability and 
retention effect [46]) and active delivery methods. Leading NP formulations that have 
been developed for active transport across the BBB have mainly focused on modifying 
the surface chemistry of a NP [47]. For example, numerous groups have conjugated 
transferrin antibodies on the NP surface and experienced increased uptake across the 
BBB due to the high abundance of transferrin receptors that are overexpressed in GBM 
[48-50]. Alternatively, a leading NP candidate developed by Dr. Jorg Kreuter (Goethe 




52]. The presence of this surfactant leads to the adsorption of a serum protein 
(apolipoprotein-E; ApoE), which binds to the receptors expressed on the endothelial cells 
of the BBB [53]. This leads to the transcytosis of the NP construct across the BBB and 
into the brain [54]. Although this NP is able to pass through the BBB, its ability to 
navigate through the heterogeneous brain tissue barrier has not been investigated.  
 To address the hindrance imposed by the BTB, studies have shielded the NP 
surface chemistry [27] or have driven NP distribution through the brain using convection 
enhanced delivery (CED) [33]. However, a combination of the two strategies has not 
been previously investigated. Our previous work employed the former strategy by 
developing sub-100nm, biodegradable NPs derived from PLGA-PEG and coated with 
cholic acid (CHA), a small molecule surfactant. When injected into brain tissue slices, 
these NPs rapidly diffused due to their densely PEG-shielded surfaces [27]. Furthermore, 
when loaded with the chemotherapeutic paclitaxel, these NPs were able to significantly 
delay the tumor growth progression of malignant glioma-bearing rodents [55].  
Here, we first compare the “brain penetrating” abilities of our biodegradable 
PLGA-PEG NPs to the gold-standard ApoE-coated NP that is able to cross the BBB. 
Furthermore, we circumvent the BBB altogether and administer our lead PLGA-PEG 
NPs into the brain using CED. We find that this combined delivery approach effectively 
avoids the BBB and also addresses the limitations imposed by the BTB, thereby 
achieving widespread therapeutic distribution in the brain that may lead to further 





4.2. Materials and Methods 
4.2.1. NP preparation, labeling, and characterization 
PLGA (75:25) (MW: 15kDa; Jinan Daigang Biomaterials Co. Ltd., Jinan, China) and 
PLGA-PEG (75:25) (25 wt% PEG; Jinan Daigang Biomaterials Co. Ltd., Jinan, China)  
NPs were formulated using the single emulsion process according to a previously 
published protocol [40]. Briefly, PLGA-PEG and PLGA polymer were fluorescently 
labeled with AlexFluor 647 and AlexaFluor 555 cadaverine dye (Molecular Probes, 
Eugene, OR) respectively as previously described [40]. Polymers were dissolved in 
dichloromethane and emulsified using a probe sonicator in 1% P80, 1% F68, 1% F127, 
1% polyvinyl alcohol (PVA), or 0.5 wt% cholic acid (Sigma Aldrich, St. Louis, MO). 
Samples were allowed to spin at 700 rpm for 3 hours to evaporate all solvent. NPs were 
filtered through a 1 m filter (Whatman, GE Healthcare, Pittsburgh, PA). PLGA-PEG 
were collected and washed using centrifugal filter units (MWCO: 100 kDa, Millipore, 
Billerica, MA) at a speed of 3600g for 12 min. PLGA NPs were collected using a two-
step procedure. NPs were centrifuged at 8000g and the supernatant was recovered and 
further ultra-centrifuged at 100,000g. The pellet was then washed once and collected 
again at 100,000g before being resuspended for further use.  
Human serum albumin NPs either uncoated (rHSA-NP), with PEG (PEG-rHSA-
NP) or Apoliprotein-E targeting ligand (ApoE-rHSA-NP) were kindly provided by Dr. 
Jorg Kreuter. Physichochemical characteristics were previously determined prior to 




NP size and surface chemistry were characterized in a standard 10 mM NaCl 
solution through dynamic light scattering and Laser Doppler Anemometry techniques 
using a Zetasizer NanoZS (Malvern Instruments, Southborough, MA). 
 
4.2.2. Rodent brain slice preparation 
Healthy rat brain tissue slices were prepared according to a slightly modified protocol of 
a previously publication [2]. The rodent brain was removed and the tissue was sliced into 
1.5 mm thick slices using a Zivic Mouse Brain slicer (Zivic instruments, Pittsburgh, PA) 
and placed in custom-made microscopy chambers. Half a microliter of fluorescently 
labeled particles was injected at a depth of 1 mm into the cerebral cortex using a 10 µL 
Hamilton Neuros Syringe (Hamilton, Reno, NV). The chambers were sealed using a 
coverslip to minimize convective bulk flow so that particle movement could be fully 
attributed to Brownian diffusion. The transport rate of particles was calculated by 
analyzing the particle trajectories in brain tissue slices as described previously [2]. 
 
4.2.3. Multiple particle tracking in rodent brain slices 
The particle trajectories were recorded as 20 s movies at an exposure of 66 ms using an 
EMCCD camera (Evolve 512; Photometrics, Tuscon, AZ) mounted on an inverted 
epifluorescence microscope (Axio Observer D1, Carl Zeiss, Hertfordshire, UK) equipped 
with a 100x oil-immersion objective. N = 3 rat brain tissue specimens were used for each 
particle type. Mean squared displacement (MSD) of particles were calculated and 




using theoretical Stokes-Einstein equation and the mean particle diameter calculated 
through dynamic light scattering.  
 
4.2.4. CED of non-adhesive PLGA-based NPs 
NPs were lyophilized overnight and resuspended at a concentration of 1 mg/mL in 0.9% 
saline. Female CF-1 mice weighing 20-30 g were anesthetized with a mixture of 
ketamine (75 mg/kg) and xylazine (7.5 mg/kg). A 2 cm sagittal incision was made on the 
head and a burr hole was made 2 mm lateral to the bregma. The loaded syringe was 
lowered to a depth of 2.5 mm below the mouse dura and a total of 2 µL of the solution 
was administered over 10 minutes at a rate of 0.2 L/min. The cannula was allowed to sit 
for 5 minutes following the completion of infusion and was then withdrawn at a rate of 1 
mm/min. The animal was then sutured (Covidien, Mundelein, Il) and placed on a heating 
pad. 
 
4.2.5. Tissue processing and image-based analysis of NP distribution  
Slices were fixed with Dako fluorescence mounting medium (Dako, Carpinteria, CA) and 
imaged using a Zeiss confocal 710 laser scanning microscope (Zeiss, Jena, Germany) in 
the GFP and Cy5 channels at 5x magnification. The presence of background fluorescence 
was determined by comparing to the striatum of the contralateral hemisphere with no 
injection. Brain slice images were quantified for fluorescent distribution of PS-PEG or 
PS-COOH NPs by running the confocal laser scanning microscope images through a 
custom MATLAB script which thresholded the images at 10% of the maximum intensity. 




not included in the quantification. The area of distribution calculated from each slice was 
multiplied by the slice thickness of 50 m and summated across all images to obtain a 
total volume of distribution. 
 
4.2.6. Statistical analysis  
Statistical testing between two groups were conducted using a two sample student t-test. 
If statistical comparisons involved more than two groups, testing was conducted with 
SPSS 18.0 software (IBM Inc.) using one-way ANOVA followed by Tukey honestly 
significant difference. Differences for t-test, ANOVA, and Tukey tests were considered 
statistically significant at p < 0.05. 
 
4.3. Results 
4.3.1 Characterization and transport of Apolipoprotein-E NPs in brain tissue 
We first tested the brain penetrating abilities of HSA-based NPs given that they are 
considered one of the leading NP for delivery across the BBB. Using multiple particle 
tracking (MPT), we tracked the individual trajectories of naked HSA-NP, PEG-coated 
HSA-NP (PEG-HSA-NP) and the gold standard Apolipoprotein-E coated NP (ApoE-
HSA–NP) in healthy rodent brain tissue and compared their mean squared displacements 
to our PS-PEG NPs. NP physicochemical characteristics are detailed in Figure 4.1A. All 
three HSA-based NPs were around 200 nm in diameter and exhibited significantly 
anionic surface charges.  
 HSA-NP, PEG-HSA-NP, and ApoE-HSA-NP all displayed completely 









Chapter 3 were able to diffuse approximately 2500 times faster than HSA-based NPs 
(Figure 4.1A, B).  
 
4.3.2 Characterization and transport of PLGA-based NPs in brain tissue 
PLGA and PEG-PLGA NPs were engineered with the varying surfactant coatings and 
collected using their respective centrifugation methods to ensure that their sizes would be 
below the previously detailed brain pore sizes [2]. All particles are sub-100 nm in 
diameter and all PEG-PLGA NPs exhibited near neutral surface charge regardless of 
surfactant choice. PLGA NPs were highly anionic except for those coated with 1% PVA 
which were also near neutral in surface charge (Table 4.1). 
 The ability of PLGA and PEG-PLGA NPs to penetrate brain tissue was conducted 
using multiple particle tracking in ex vivo healthy rodent brain tissue slices. Interestingly, 
both PLGA and PEG-PLGA NPs that were coated with surfactants that have previously 
been implicated to help in NP crossing of the BBB (P80 and F68) demonstrated 
completely immobilized motion (Figure 4.2). In fact, their MSD were similar, if not 
slower, than the MSD of ApoE-HSA-NP at a timescale of  = 1 second (Table 4.1). PEG-
PLGA NPs coated with 1% F127 or 1% PVA exhibited 6-fold and 5.4-fold increased 
MSD respectively as compared to the MSD of ApoE-HSA-NP. Again, non-PEGylated 
PLGA NPs coated with these same surfactants were immobilized. On the other hand, 
PEG-PLGA NPs formulated in ultrapure water or 0.5% CHA diffused 19-fold and 80-





4.3.3 Volume of distribution of PLGA-based NPs following CED 
Following our ex vivo characterization, we wanted to investigate whether the improved 
diffusion of PLGA-PEG NPs formulated with 0.5% CHA could translate to improved 
distribution in vivo following administration using CED. Indeed, compared to similarly 
sized and formulated PLGA (0.5% CHA) NPs, PEG-PLGA (0.5% CHA) NPs were able 
to achieve widespread distribution throughout the striatum (Figure 4.3A). In fact, the 
final Vd of PEG-PLGA NPs was 0.48 mm
3
, which was a 12-fold improvement over the 





Effective delivery of NP therapeutics to the brain for treatment of primary brain tumors 
such as GBM requires addressing two main barriers: 1) the blood brain barrier and 2) the 
brain tissue barrier. Biodegradable NPs remain the main delivery vehicle of choice given 
its tailorable size and surface chemistry; however, the main focus has been on developing 
NPs specifically for overcoming the BBB instead of also addressing the nascent 
understanding of the necessary design criteria for effective NP delivery through the BTB. 
The inability to tackle both barriers has resulted in limited advancements in utilizing 
nanotechnology strategies for improving therapeutic outcome of GBM patients. In this 
chapter, we begin by demonstrating that the optimized biodegradable NPs that have been 
designed for passage through the BBB fail to address the hindrances of the BTB. In 
comparison, we find that our PLGA-PEG based NPs are able to rapidly diffuse in brain 




CED, these NPs achieve widespread distribution in the rodent striatum and represent a 
promising strategy for the treatment of GBM. 
 The use of surfactant coatings on biodegradable NP has been widely investigated 
given the ease of adsorbing these different molecular chains to the NP surface. This 
modification has been shown to stabilize the NP and maximize drug encapsulation 
efficiency, both essential considerations for effective drug delivery [56]. In addition, the 
use of specific surfactants has been shown to have further implications for overcoming 
both the BBB and BTB [54]. Our previous work has shown that a CHA surfactant coated 
on the surface of PLGA-PEG NPs can lead to improved NP distribution [40]. Here, 
PLGA-PEG NP coated with our surfactant of choice, CHA, diffuse faster than ApoE 
coated HSA NP in the brain tissue. In fact, P80 coated NP, which has been shown to 
associated with ApoE and facilitate BBB transcytosis, are immobilized once in the brain 
parenchyma. Thus, although systemically administered P80 coated NPs and HSA-NP are 
able to transcytose across the BBB, they would not be able to distribute through the brain 
parenchyma. However, we do note that Kreuter and coworkers have shown that these P80 
coated NPs traffic to the cytoplasm of neurons in the brain [54]. In light of our findings, 
the transport of Kreuter et al.’s P80 coated NPs through the brain parenchyma is likely an 
active transport process, which traffics them away from the endothelial cells of the BBB 
and localizes them within specific neurons. 
Surface modification to render a NP surface non-interactive is an essential factor 
towards maximizing therapeutic distribution in the brain parenchyma. In addition to steric 
limitations, distribution of PLGA-based NP systems is most likely hindered by 




PLGA NPs allows them to more effectively distribute as compared to its non-shielded 
counterpart. The importance of appropriate NP design and delivery is further reflected by 
a promising study recently conducted by Zhou et al. who observed significant survival 
benefits when glioma-bearing rodents were treated with paclitaxel-loaded PLGA NPs that 
were coated with PVA surfactant and intracranially administered with CED [33]. 
Interestingly, we found that PLGA-PEG NPs coated with PVA surfactant did not exhibit 
brain penetrating abilities; rather, these NPs were hindered and immobilized by the brain 
ECM. The discrepancy between our findings and Zhou et al. can be attributed to their 
method of administration (CED) and higher NP concentration (100 mg/mL) that was 
infused into the brain, which has previously been shown to significantly improve NP 
distribution (also observed in Figure 3.2). In our study, we demonstrate that brain 
penetrating PLGA-PEG NPs coated with CHA surfactant can distribute to a large volume 
of the rodent striatum when administered via CED, even if delivered at very low 
concentrations (1 mg/mL). Thus, this CHA-coated PLGA-PEG NP will enable the 
delivery of highly cytotoxic drugs whose toxicities would be prohibitive if administered 
at high concentrations. 
 
4.5. Conclusion 
In this chapter, we compared the “brain penetrating” abilities of our lead, PLGA-PEG 
NPs to the HSA-NPs that have been engineered to overcome the BBB. We believe that 
when delivering a therapeutic to the brain, the presence of the brain tissue barrier must be 
heavily weighted, perhaps even moreso in comparison to the BBB. Although our brain 




delivery using CED can avoid the BBB altogether and achieve widespread therapeutic 
distribution in the brain. Thus, we believe that the delivery of a non-adhesive PLGA NP 
into the brain using CED represents a promising treatment platform for the delivery of 





Figure 4.1: Characterization of human serum albumin nanoparticles (HSA-NP) (A) 
Physicochemical characteristics of PS-NP and HSA-NP. * Values provided by Kreuter and 
coworkers. (B) Mean squared displacement (MSD) of tracked nanoparticles in healthy 






Table 4.1: Physicochemical properties of biodegradable PLGA and PLGA-PEG 
nanoparticles coated with varying surfactants. Size and ζ-potential were measured 








Figure 4.2: Ex vivo characterization of PLGA and PEG-PLGA NP. Mean squared 
displacement (MSD) at a timescale of 1 sec for individual PLGA-based NP 






Figure 4.3: In vivo distribution of therapeutic PLGA nanoparticles in mouse striatum 
administered via CED (A, B) Representative coronally-sliced images of PLGA-PEG (red) 
and PLGA (green) nanoparticles infused in 0.9% saline Data represent the average of N ≥ 3 
mouse brain specimen for each solution. (B) Quantified PLGA-PEG and PLGA volume of 
distributions in rodent striatum. Inset depicts the Vd of PLGA based nanoparticles. *P < 




5. DEVELOPMENT AND IN VIVO CHARACTERIZATION OF A 




Patients with neurological diseases, including Parkinson’s disease, Alzheimer’s disease, 
brain tumors and most neurogenetic disorders, suffer from severe debilitating symptoms 
and lack of effective treatments. The accumulated knowledge of specific genetic targets 
that can alter or reverse the progression of central nervous system (CNS) diseases makes 
gene therapy an attractive therapeutic strategy [57, 58]. Multiple preclinical and clinical 
studies have aimed to improve the delivery of nucleic acids to the CNS using leading 
viral or non-viral gene vectors, with specific focus on enhancing the level and distribution 
of transgene expression throughout the brain tissue [57, 59].  
Viral gene vectors, though relatively efficient, have been limited by low 
packaging capacity, technical difficulties in scale-up, high cost of production [60] and/or 
risk of mutagenesis [61]. Furthermore, despite the immune-privileged nature of the CNS, 
neutralizing immune responses may occur with repeated administrations or after prior 
exposures [25, 58, 62-65]. Non-viral gene vectors are an alternative strategy for gene 
delivery without many of the limitations of viral vectors [57]. Cationic polymer-based 
gene vectors provide a tailorable platform for DNA condensation and gene transfer in 
vitro and in vivo. The positive charge density allows for stable compaction of negatively 
charged nucleic acids [66, 67], protecting the nucleic acids from enzymatic degradation 
[68]. Also, the protonatable amines provide increased buffering capacity that may 
facilitate endosome escape via the “proton sponge effect”, leading to transfection [69]. A 




enabling the design of gene vector platforms with diverse physicochemical profiles and in 
vivo behaviors [70, 71].  
However, non-viral gene vectors must overcome numerous biological barriers to 
reach target cells in the brain [57]. Various strategies have been developed to manipulate 
or bypass the BBB [72, 73], which is the primary barrier to the systemic delivery of gene 
vectors to the brain. These approaches include, but are not limited to, direct 
administration to the CNS [74] and reversible disruption of the BBB via focused 
ultrasound [75] or chemical agents [76]. However, once beyond the BBB, the anisotropic 
and electrostatically charged brain ECM found between brain cells has been widely 
recognized as another critical barrier [2, 77, 78]. This BTB hampers widespread 
distribution of macromolecules and NP in the brain, thereby limiting their access to target 
cells in disseminated neurological diseases [2, 25, 26, 77]. Given that polymeric gene 
vectors are typically derived from cationic backbone polymers, the negatively charged 
components of the ECM, comprising hyaluronan, chondroitin sulfate, proteoglycans, link 
proteins and tenascins, represent a significant electrostatic barrier to the penetration of 
DNA-NP [77, 79].  
Convection enhanced delivery (CED) can further enhance the distribution of 
therapeutics by providing a pressure gradient during intracranial administration [20]. 
However, CED is unlikely to provide a significant benefit if DNA-NP are trapped in the 
brain parenchyma due to adhesive interactions and/or steric obstruction. Previous reports 
have demonstrated that, even following CED, the interactions between positively charged 
gene vectors and the negatively charged ECM confine NP to the point of injection and 




parenchyma  [26, 80, 81]. Thus, designing particles with surfaces that minimize 
interactions with the brain ECM is critical for achieving CED-mediated enhanced particle 
distribution in the brain [20, 80].  
In this study, we aimed to develop a DNA-NP platform with the physicochemical 
properties required for efficient brain penetration by polymeric NP, namely, a non-
adhesive surface coating and small particle diameter in comparison to the average ECM 
mesh spacing [2]. To formulate a compact, colloidally-stable gene vector platform for 
CNS delivery, we were guided by our previous work toward optimizing PEG density to 
formulate gene vectors capable of efficiently penetrating human mucus secretions [82, 
83]. Here, we formulated densely PEGylated brain-penetrating DNA-NP (DNA-BPN), 
conventionally PEGylated (lower density) DNA NP (DNA-CPN), and un-PEGylated 
DNA NP (DNA-UPN) and characterized their toxicity, cell uptake, and transfection 
efficiency in vitro. We then used high resolution MPT to compare their transport rates in 
freshly excised ex vivo rodent brain tissues. Finally, we investigated NP distribution and 
transfection throughout the brain tissue following administration in vivo by CED. 
 
5.2. Materials and Methods 
5.2.1. Gene vector synthesis and DNA labeling 
Methoxy PEG N-hydroxysuccinimide (mPEG-NHS, 5 kDa, Sigma-Aldrich, St. Louis, 
MO) was conjugated to 25 kDa branched polyethyleneimine (PEI) (Sigma-Aldrich, St. 
Louis, MO) to yield a PEG5k-PEI copolymer as previously described [82]. Briefly, PEI 
was dissolved in ultrapure distilled water, the pH was adjusted to 7.5 – 8.0 and mPEG-






C. The polymer solution was extensively dialyzed (20,000 MWCO, Spectrum 
Laboratories, Inc., Rancho Dominguez, CA) against ultrapure distilled water and 
lyophilized. Nuclear magnetic resonance (NMR) was used to confirm PEG: PEI ratios of 
8, 26, 37 and 50. 1H NMR (500 MHz, D2O): δ 2.48 – 3.20 (br, CH2CH2NH), 3.62 – 
3.72 (br, CH2CH2O). The poly-L-lysine 30-mer (PLL) and PEG5K-PLL block 
copolymers were synthesized and characterized as previously published.[82, 84] The 
lyophilized polymers were dissolved in ultrapure distilled water and pH was adjusted to 
~6.5 – 7. 
The pd1GL3-RL plasmid DNA was a kind gift from Professor Alexander M. 
Klibanov (M.I.T) and pEGFP plasmid was purchased by Clontech Laboratories Inc. 
(Mountainview, CA). The plasmid DNA was propagated and purified as previously 
described [82]. Mirus Label IT® Tracker™ Intracellular Nucleic Acid Localization Kit 
(Mirus Bio, Madison, WI) was used to fluorescently tag plasmid DNA with a Cy3 or Cy5 
fluorophore. Gene vectors were formed by the drop-wise addition of 10 volumes of 
labeled or non-labeled plasmid DNA (0.2 mg/ml) to 1 volume of a swirling polymer 
solution. PEI solutions were prepared at previously optimized nitrogen to phosphate 
(N/P) ratio of 6 and at PEG5k-PEI to PEI molar ratio of 3. For the formulation of free PEI 
(DNA-UPN) and (PEG5k)8-PEI (DNA-CPN) based gene vector controls, the PEI 
solutions were prepared at N/P ratio of 6 using 100% of free PEI or (PEG5k)8-PEI, 
respectively. For fluorescence imaging, Cy3- or Cy5-labeled DNA was used to assemble 
fluorescently labeled gene vectors. The plasmid/polymer solutions were incubated for 30 
min at room temperature to form gene vectors. Gene vectors were washed twice with 3 




Ultra Centrifugal Filters (100,000 MWCO, Millipore Corp., Billerica, MA) to remove 
free polymers. DNA concentration was determined via absorbance at 260 nm using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
PEG-PLL gene vectors were similarly prepared at an N/P ratio of 2 as previously 
described [82, 84, 85]. 
 
5.2.2. NP physicochemical characterization and in vitro stability 
Hydrodynamic diameter, ζ-potential and polydispersity index (PDI) were measured in 10 
mM NaCl at  pH 7.0 by dynamic light scattering and laser Doppler anemometry, 
respectively, using a Nanosizer ZS90 (Malvern Instruments, Southborough, MA). Gene 
vectors were imaged using transmission electron microscopy (TEM, Hitachi H7600, 
Japan) to determine their morphology and dimensions. PEI gene vector stability was 
assessed by incubating gene vectors in artificial cerebrospinal fluid (aCSF; Harvard 
Apparatus, Holliston, MA) at 37 
o
C and conducting dynamic light scattering every 30 
min for 24 h. At 1 h of incubation, a fraction of the NP solution was used for TEM. 
 
5.2.3. Ex vivo brain penetration of non-adhesive DNA-NP 
Multiple particle tracking (MPT) was used to estimate the MSD of fluorescent gene 
vectors in ex vivo rodent brain slices as previously described [2]. Briefly, brains were 
harvested from adult Fischer rats and incubated in aCSF for 10 min on ice. The brains 
were sliced into 1.5 mm coronal slices using a Zivic brain matrix slicer (Zivic 
Instruments, Pittsburgh, PA) and placed on custom made slides. Half a microliter of 




using a 50 μl Hamilton Neuro Syringe (Hamilton, Reno, NV) mounted on a stereotaxic 
frame. Tissues were covered by a 22 mm x 22 mm coverslip to minimize tissue 
movement and bulk flow. Particle trajectories were recorded over 20 s at an exposure 
time of 66.7 ms by an Evolve 512 EMCCD camera (Photometrics, Tucson, AZ) mounted 
on an inverted epifluorescence microscope (Axio Observer D1, Zeiss; Thornwood, NY) 
equipped with a 100x/1.46 NA oil-immersion objective. Movies were analyzed with a 
custom made MATLAB code to extract x, y-coordinates of gene vector centroids over 
time and calculate the MSD of each particle as a function of time [2, 86]. The spatial 
resolution to the noise/signal ratio correlation was estimated using immobilized gene 
vectors on a glass slide [87, 88]. We estimated the average resolution of our MPT 
experiments to be ~0.009 µm
2 
at 1 s. At least three rat brains were used per gene vector 
type, and at least 500 gene vectors were tracked per brain sample. The ensemble-
averaged MSD (<MSD>) for all gene vectors in a sample was calculated and then 
averaged over different samples as a function of time. Histograms were generated from 
the MSD data for each individual vector at a time scale of 1 s. The theoretical MSD of 
gene vectors in aCSF was calculated using the Stokes-Einstein equation and the mean 
particle diameter calculated through dynamic light scattering.  
 
5.2.4. CED administration of brain penetrating DNA-NP 
To study the distribution of PEI-based gene vectors following CED in the rodent 
striatum, six rats for each vector type were used. A 33 gauge 50 µl Hamilton Neuro 
Syringe mounted to a stereotaxic headframe was lowered to a depth of 3.5 mm. A 20 µl 




concentration of 500 µg/ml for each particle type in normal saline was administered. The 
rate of infusion was set at 0.33 µl/min, using a Chemyx Inc. Nanojet Stereotaxic syringe 
pump (Chemyx, Stafford, TX). Animals were sacrificed 5 h following the injection. To 
examine the concentration-dependence of particle distribution, we also performed co-
injections at half the plasmid concentration, 250 µg/ml for each particle type, in normal 
saline. 
 
5.2.5. Expression of reporter transgene following CED of brain penetrating DNA-NP 
To assess the distribution of transgene expression following CED administration of gene 
vectors, at least four rats for each particle type were used; plasmid encoding fluorescent 
eGFP reporter protein with a cytomegalovirus (CMV) promoter was complexed into the 
various PEI-based gene vector formulations and infused in a 20 µl solution of 1 mg/ml 
plasmid solution using the same parameters described above. Animals were sacrificed 48 
h following CED administration, and harvested brains were fixed in 4% formaldehyde. 
 
5.2.6. Image based quantification of DNA-NP distribution and transgene expression 
Freshly harvested brains were fixed in 4% formaldehyde overnight followed by a 
gradient sucrose solutions before cryosection. Tissues were sectioned coronally into 100 
µm thick slices using Leica CM 1905 cryostat. Slices were stained with DAPI (Molecular 
Probes, Eugene, OR) to visualize cell nuclei, and imaged for the fluorescence originated 
from DAPI, Cy3 and Cy5 or Alexa Fluor 488 (eGFP) using confocal LSM 710 
microscope (Carl Zeiss; Hertfordshire, UK) under 5x and 10x magnification. Settings 




rat brains. Laser power, pinhole, gain, offset and digital gain were selected separately for 
each magnification and kept constant throughout the study.  
The volume of gene vector distribution following CED administration was 
quantified using a custom MATLAB script that subtracted the background fluorescence 
and thresholded the fluorescent intensities at 10% of the maximum intensity. NP 
fluorescence in the white matter tracts due to backflow was excluded from quantification. 
Every 100 µm slice within 2 mm of the injection plane was imaged. The area of 
distribution on each slice was summated to calculate the total volume of gene vector 
distribution. The identical process was utilized for the analysis of the distribution of 
transgene expression mediated by various PEI-based gene vectors carrying eGFP 
plasmid. To reconstruct three dimensional images of NP distribution and distribution of 
transfection within the rodent striatum, we stacked and aligned the previously acquired 
images using Metamorph ® Microscopy Automation & Image Analysis Software 
(Molecular Devices, CA). We used Imaris ® Software (Bitplane, CT) to create 3D 
isosurfaces of the reconstructed images.  
 
5.2.7. Quantification of transgene expression using Western Blot 
For western blot analysis of in vivo transfection following CED of gene vectors, three rats 
for each particle type were used and the same experimental procedures followed for 
imaging-based analysis of distribution of transfection were used. Animals were sacrificed 
48 h following CED administration and immediately placed on ice and a 4 mm thick 
coronal slice of the striatum from -2 mm to 2 mm from the injection site was dissected 
and stored in -80
o




and anti-β-actin:sc-47778 (Santa Cruz Biotechnology, Santa Cruz, CA), were used for the 
detection of transgene expression (eGFP) and housekeeping protein (actin), respectively. 
Brain tissues were lysed using brief sonication in ice PBS buffer (1 mM PMSF, and 1 
µg/ml each of aprotinin, leupeptin, and pepstatin A). Sampling buffer (10% glycerol, 2% 
SDS, 62.5 mM Tris–HCl, 2% β-mercaptoethanol, pH 6.8) was added and samples were 
boiled at 100
o
C for 10 min. Samples were resolved by SDS–polyacrylamide gel 
electrophoresis (PAGE) and proteins on the gels were transferred to nitrocellulose (Bio-
Rad, Hercules, CA) using a semidry blotter (Bio-Rad, Hercules, CA). The membrane was 
blocked with 3% BSA in TBST (10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.5% Tween-
20) and incubated overnight at 4 °C with primary antibodies. Immunoblots were 
visualized by enhanced chemiluminescence method. Quantification of western blot 
results was performed using the Multi Gauge program (Fujifilm, Tokyo, Japan) [89]. 
 
5.2.8. In vivo safety of DNA-NP  
To evaluate the safety profile of the gene vectors in vivo following CED administration, 
three rats for each group were used. Various PEI-based gene vector formulations were 
infused in a 20 µl solution at a 1 mg/ml plasmid concentration as described above. A 
normal saline solution was infused as a negative control. Animals were sacrificed 4 d 
following administration and the harvested brains were fixed in 4% formaldehyde, 
processed, sectioned and stained with hematoxylin and eosin. Blind histopathological 
analysis was performed by a board certified neuropathologist and tissues were scored 
from 0-3 for indications of inflammation and hemorrhage (0: no 





5.2.9. Statistical analysis  
Statistically significant differences between two groups were analyzed with a two-tailed 
Student’s t test assuming unequal variances or paired student’s t test when allowed. 
Multiple comparisons were performed using one-way analysis of variance (ANOVA), 
followed by post hoc test using SPSS 18.0 software (SPS S Inc., Chicago, IL). 
 
5.3. Results 
5.3.1. In vitro characterization and stability of DNA-NP 
To effectively shield the positive surface charge intrinsic to cationic gene vectors, we 
formulated gene vectors using copolymers of polyethyleneimine (PEI) conjugated to 
multiple 5 kDa PEG molecules (PEG5k-PEI) with a range of PEG to PEI molar ratios. As 
previously reported, PEGylation of cationic polymers may have a negative influence on 
DNA complexation due to reduction of available positive charges and additional steric 
hindrance by the PEG chains after conjugation [90]. Thus, using only highly PEGylated 
PEI to condense DNA copolymers yields loose, unstable gene vectors that are not likely 
to retain their stability in biological environments [82]. In order to achieve compact and 
colloidally stable gene vectors, we formulated vectors with a blend of PEG5k-PEI and free 
PEI, with 25% of the total amines deriving from free PEI [82]. Using a fixed amount of 
free PEI, we achieved DNA compaction into ~50 nm DNA NP using PEG5k-PEI 
copolymers with a wide range of PEG to PEI molar ratios. Importantly, we found that the 
use of a copolymer with a PEG to PEI ratio of 26, which is substantially higher than 




neutral 𝜁-potential (Table 1) (DNA-BPN); near-neutral 𝜁-potential has been shown to be 
key to enabling NP diffusion in brain tissue [2]. We also prepared DNA-CPN consisting 
of PEGylated PEI with a more conventional PEG to PEI ratio of 8 [55, 90, 93], and un-
PEGylated PEI DNA NP (DNA-UPN). The physicochemical properties of DNA-BPN, 
DNA-CPN and DNA-UPN are summarized in Table 5.1. Of note, DNA-CPN possessed a 
larger particle diameter and more positive surface charge compared to DNA-BPN, (59 
nm and 9.3 mV for DNA-CPN; 43 nm and 2.9 mV for DNA-BPN) suggesting looser 
compaction and/or inferior surface coating of DNA-CPN. 
To predict the particle stability of gene vectors following in vivo administration, 
we characterized in vitro stability in artificial cerebrospinal fluid (aCSF) at 37
o
C over 
time (Figure 5.1A). DNA-UPN aggregated immediately after addition to aCSF; the 
hydrodynamic diameter increased 8.3-fold, from 47 nm ± 2 nm to 392 nm ± 32 nm. After 
7 h, the polydispersity index (PDI) was greater than 0.5, indicating loss of colloidal 
stability. DNA-CPN diameter increased ~3-fold 30 min after addition to aCSF, from 59 
nm ± 1 nm to 172 nm ± 5 nm, and then remained stable at the larger size for the 
remaining 24 h. We found that DNA-BPN exhibited improved stability in aCSF 
compared to both DNA-UPN and DNA-CPN. DNA-BPN size remained unchanged over 
the first 30 min in aCSF at 50 nm ± 17 nm, followed by a 1.6-fold increase in diameter 
that remained stable over the remaining 24 h (Table 5.1, Figure 5.1A). These 
observations were further confirmed by transmission electron micrographs (TEM) of 
gene vectors in ultrapure water (Figure 5.1B, upper row) and after 1 h incubation in aCSF 
at 37
o
C (Figure 5.1B, lower row). Incubation of DNA-UPN in aCSF resulted in the 




of aggregation, while DNA-BPN modestly increased in size, but did not appear to 
aggregate.  
 
5.3.2. Ex vivo brain penetration of DNA-NP with varying PEG densities 
We next used MPT to assess the diffusion of DNA-BPN, DNA-CPN and DNA-UPN in 
the brain parenchyma. We have previously demonstrated, using model NP, that MPT 
results in ex vivo brain tissue predicts well NP penetration into the brain parenchyma in 
vivo [2].  As expected, due to their positive surface charge, the DNA-UPN were largely 
immobilized by the brain ECM, as shown by their constrained, non-Brownian trajectories 
(e.g. Figure 5.2A). Similarly, the average DNA-CPN exhibited hindered motion, though 
not completely immobilized (Figure 5.2A). In contrast, the trajectory of a typical DNA-
BPN spanned much greater distances, indicating relatively unhindered diffusion in brain 
tissue (Figure 5.2A). At a timescale of 1 s, the ensemble-averaged mean squared 
displacement (<MSD>) of DNA-BPN was 5- and 29-fold higher than that of DNA-CPN 
and DNA-UPN, respectively (Figure 5.2B). The diffusion rates of DNA-UPN and DNA-
CPN in brain tissue were 6,900- and 930-fold lower than their theoretical diffusion rates 
in aCSF, respectively, while DNA-BPN moved only 260-fold slower in brain than in 
aCSF (Table 5.1). When examining histograms displaying the range of logarithmic MSD 
values (log10MSD) for individual gene vectors, we found that the transport behavior was 
largely unimodal for DNA-UPN and DNA-BPN; the majority of DNA-UPN displayed 
low MSD values, whereas most DNA-BPN exhibited increased MSD values indicative of 
diffusion in brain tissue. DNA-CPN were largely immobilized in brain tissue, but a minor 




DNA NP as having log10MSD ≥ -1 [86], we found that 10.3%, 32.9% and 63% of DNA-
UPN, DNA-CPN and DNA-BPN, respectively, were able to diffuse in the brain 
parenchyma. To test whether the enhanced ex vivo diffusion in brain tissue would 
improve the distribution of the vectors in the brain parenchyma in vivo, we performed a 
bolus co-injection of fluorescently labeled DNA-CPN and DNA-BPN in the rodent 
striatum. As shown in Figure 5.2D, DNA-CPN largely remained localized to the injection 
site, whereas DNA-BPN spread approximately 300 µm from the injection site only 2 h 
after administration.  
 
5.3.3. DNA-NP volume of distribution following CED administration 
We next aimed to determine the effect of vector surface characteristics on distribution in 
brain following CED. To directly compare the spatial distribution of the gene vectors, we 
co-infused Cy5-labeled DNA-BPN and Cy3-labeled DNA-CPN. DNA-BPN distributed 
homogeneously throughout the rodent striatum, whereas DNA-CPN were confined in the 
injection site (Figure 5.3A, B). Within the coronal plane of injection, DNA-BPN covered 
a 3-fold larger tissue area than DNA-CPN (Figure 5.3C, p < 0.05). Moreover, the overall 
volume of distribution in the brain achieved with DNA-BPN was found to be 3.1-fold 
higher than the volume of distribution achieved with DNA-CPN (Fig. 5.3D).  
 
5.3.4. Widespread delivery and high levels of a reporter transgene 
We then sought to determine whether increased tissue distribution would also lead to an 
increase in the volume of tissue transfected following CED administration of gene 




animals demonstrated significant eGFP expression surrounding the injection site (Figure 
5.4A-B, D-E). In contrast, DNA-BPN provided widespread transfection throughout the 
rat striatum (Figure 5.4C, F), which correlated well with the gene vector distribution 
analysis (Fig. 5.3A, B). In particular, DNA-BPN resulted in a statistically significant (p < 
0.05) increase in the eGFP transgene expression with a 2.4- and 3.2-fold higher volume 
of tissue transfection compared to DNA-CPN and DNA-UPN, respectively (Figure 5.4G).  
We also quantitatively determined total transgene eGFP expression mediated by CED of 
DNA-UPN, DNA-CPN and DNA-BPN, using western blot analysis. DNA-BPN 
demonstrated a statistically significant, 2-fold higher overall transgene expression in the 
striatum in comparison to DNA-CPN and DNA-UPN (Figure 5.4H). 
 
5.4. Discussion 
As previously discussed with drug delivery, efficacious gene therapy for diffuse and 
debilitating CNS disorders requires that transgene expression occur throughout the 
broadly disseminated, diseased area at therapeutically relevant levels [25, 94, 95]. 
Regardless of delivery method, the limited spatial distribution of non-viral gene vectors 
in the brain remains a key challenge to achieving clinically-relevant therapeutic results 
[94, 96]. In this chapter, we demonstrated that exceptionally dense PEG coatings, only 
achieved by blends of PEG-PEI and PEI, are critical to NP stability, safety, and 
distribution and transfection within the brain. We further establish that the BPN gene 
vector platform is non-adhesive to the brain parenchyma, leading to improved 
distribution in the brain. Further, the synergistic effect of combining polymeric gene 




provided by CED resulted in highly efficient and widespread transgene expression in the 
brain parenchyma. Importantly, this was achieved with no signs of vector-induced 
toxicity. This strategy provides a tailorable polymer-based platform that may 
significantly improve the efficacy of non-viral gene therapy in CNS diseases.  
NP diffusion in the brain predominantly takes place through the narrow, tortuous 
space between cells [77]. The ECM, the main component of the extracellular space, 
imposes an adhesive and steric barrier to the movement of NP through the brain 
parenchyma. Non-specific electrostatic interactions with the abundant negative charges of 
the ECM hinder the diffusion of poorly-shielded cationic polymer-based gene vectors 
[79, 97], as shown with DNA-UPN (uncoated) and DNA-CPN (less densely coated) in 
this study. Hence, rapid brain penetration of DNA-BPN is most likely attributed to the 
efficient shielding of the positive surface charge intrinsic to the cationic polymer-based 
gene vectors. Moreover, the dense surface PEG coating achieved by blending highly 
PEG-conjugated polymer with unmodified polymer allows DNA-BPN to retain their 
compact sub-100 nm size in physiological conditions (i.e. CSF) required to move through 
the pores in the ECM without being hindered by steric obstruction. In comparison, the 
loose compaction, lack of stability and the tendency towards aggregation of 
conventionally PEGylated cationic particles, including DNA-CPN, does not allow for 
efficient penetration through the large proportion of ECM pores that are smaller than 200 
nm in diameter [2, 26]. These results demonstrate the importance of designing gene 
vectors capable of overcoming both the adhesive interactions and steric hindrance 




CED has been applied to further enhance the distribution of locally administered 
therapeutics. However, CED of non-PEGylated liposomal non-viral gene vectors for the 
treatment of unresectable or recurrent glioblastoma has demonstrated limited success in a 
phase I/II clinical trial. Voges et al. underlined the fact that, even following CED, the 
heterogeneous ECM can act as a barrier, hence limiting the spatial distribution of gene 
vectors [25, 98]. Namely, the physicochemical characteristics of gene vectors leading to 
adhesive and/or steric interactions with the brain parenchyma significantly impact their 
flow through brain tissue [20, 26]. Previous studies have reported that cationic charge, 
even if shielded, greatly restricts the convection of NP away from the point of 
administration [26, 94]. Here, we demonstrate that the diffusion of DNA-BPN in the 
brain parenchyma translates to enhanced distribution of gene vectors in vivo and, 
therefore, widespread transgene expression throughout the brain when administered using 
CED. It should be noted that a high density surface coating is required to achieve 
improved CED-facilitated distribution of gene vectors; the insufficiently shielded DNA-
CPN were unable to escape the injection site and failed to mediate enhanced distribution 
of transgene expression compared to unshielded DNA-UPN following CED.  
PEGylation as a stealth coating strategy has previously been shown to decrease 
cell uptake, endosome escape and subsequent transgene expression [99, 100]. However, 
we found that PEGylation of cationic polymer-based gene vectors did not decrease entry 
in primary astrocytes (rat, rabbit) or 9L glioma, as demonstrated in previous reports  [101, 
102], but led to significantly lower transfection efficacy in vitro [103, 104]. The increased 
stability of DNA-BPN may decrease in vitro transfection efficiency by hindering DNA 




capacity and subsequent endosome escape by the PEI-based vectors [103, 105]. 
Regardless, CED administration of DNA-BPN resulted in double the total amount of in 
vivo transgene expression in comparison to DNA-UPN and DNA-CPN, suggesting that 
the ability of DNA-BPN to maintain small size and reach and transfect cells over a larger 
area of the striatum more than offsets the inferior intracellular delivery capacity often 
observed with PEG-coated gene vectors.  
Although cationic polymer-based gene vector have been safely tested in clinical 
trials [106], their possible cytotoxicity remains a concern [90, 92]. In good agreement 
with previous observations [90, 107, 108], conventional PEGylation (i.e. DNA-CPN) was 
not sufficient to significantly improve the in vitro safety profile of cationic polymer-
based gene vectors. However, we demonstrated that the dense PEG coatings achieved 
using our polymer blending approach significantly decreased the toxicity of PEI-based 
gene vectors. DNA-BPN was associated with a favorable safety profile, similar to the 
widely used PEG-PLL NP system shown to be safe in animal  brain [109, 110] and lung 
[111, 112], as well as the human airways [113]. The reduced toxicity of DNA-BPN in 
vivo in combination with the widespread distribution in the brain when administered by 




Non-viral gene vectors have emerged as a promising platform for the treatment of CNS 
diseases. However, achieving high spatial distribution of therapeutically relevant 




designing cationic polymer-based gene vectors that can penetrate through the brain 
parenchyma, leading to enhanced vector distribution throughout the entire striatum 
following CED. This strategy can be adapted to a variety of cationic polymers with 
different attributes that may further enhance gene transfer to the brain [82]. The 
combination of the DNA-BPN gene vector technology with plasmids encoding for 
sustained or selective expression can further enhance the transfection profile of DNA-
BPN [110, 114]. The combined result of high-level and widespread transgene expression 
achieved with DNA-BPN has promise for improving the therapeutic efficacy of gene-








Table 5.1: Physicochemical properties and diffusivity of gene vectors in rodent cortical 
tissue.  
























DNA-UPN 0 47 ± 2 26 ± 1.2 0.15 1071 ± 53 6900 
DNA-CPN 1.6 59 ± 1 9.3 ± 0.5 0.17 193 ± 4 930 
DNA-BPN 3.9 43 ± 5 2.9 ± 0.3 0.19 80 ± 9 260 
a
 PEG/PEI weight to weight ratio used to formulate respective NP. 
b 
Size, ζ-potential and polydispersity (PDI) were measured by dynamic light scattering (DLS) in 10 mM 
NaCl at pH 7.0 and are presented as an average of at least 3 measurements ± standard error of the mean 
(SEM). 
c 
Hydrodynamic diameter in aCSF was measured by DLS following incubation in aCSF at 37 
o
C for 1 h. 
d 
MSD at 1 s was measured using MPT of fluorescently labeled gene vectors in rodent brain slice. NP 














Figure 5.1: Gene vector stability (A) Gene vector hydrodynamic diameter in aCSF at 37 
o
C was 
measured by dynamic light scattering (DLS). Measurements were taken every half an hour up to 24 
hours or until polydispersity (PDI) > 0.5. Data represents the mean ± SEM. (B) Transmission electron 
microscopy images of gene vectors in ultrapure water (top panel) and following 1 h incubation in aCSF 
at 37 
o






Figure 5.2: Gene vector penetration of rodent brain tissue (A) Representative particle 
trajectories over 20 s in ex vivo rodent brain tissue. Trajectories shown are of particles that had an 
MSD equal to the ensemble average at a time scale of 1 s. Scale bar = 0.25 µm (B) Ensemble-
averaged geometric mean of MSD of PEI-based gene vectors as a function of time. Data represent 
the ensemble average of at least three independent experiments, with n ≥ 500 particles tracked for 
each experiment. (C) Histograms of individual MSD of respective gene vectors from at least three 
independent experiments at a timescale of τ = 1 s. (D) In vivo spread of Cy5- labeled DNA-CPN 
(Green) and Cy3-labeled DNA-BPN (Red) following bolus co-injection in the striatum. Scale bar = 
100 μm. Co-localization of DNA-BPN and DNA-CPN in each image is represented as yellow. 





Figure 5.3: In vivo distribution of PEI-based gene vectors following CED (A) 
Representative distribution of labeled Cy3 DNA-CPN (green) and Cy5 DNA-BPN 
(red) in rat striatum using confocal microscopy; DAPI staining for cell nuclei (blue). 
Colocalization of DNA-BPN and DNA-CPN in each image represented as yellow. 
Scale bar 1 mm. (B) Representative 3D reconstruction of labeled Cy3 DNA-CPN 
(green) and Cy5 DNA-BPN (red) distribution in the rat striatum following CED.  (C) 
Image-based MATLAB quantification of area of distribution of PEI-based NP as a 
function of distance from the injection site (n = 6). (D) Summated image-based 
MATLAB quantification of volume of distribution for DNA-BPN and DNA-CPN (n 







Figure 5.4: In vivo distribution and overall level of eGFP transgene expression following 
CED of various PEI-based gene vectors carrying eGFP plasmid DNA (A-C) Representative 
stacked and aligned confocal images of eGFP expression (Green) following administration of the 
respective PEI-based gene vectors in the rodent caudate putamen. Scale bar = 1mm. (D-F) 
Isosurface 3D re-construction of distribution of in vivo eGFP expression using multiple 
sequential confocal fluorescence images of respective PEI-based gene vectors. (G) Image-based 
MATLAB quantification of volume of distribution of eGFP expression *p < 0.05 (n = 4-6). (H) 
Transgene expression following NP CED administration in rodent striatum. eGFP expression 
was analyzed using Western blot. The band quantification was performed using Multi Gauge 
software (Fujifilm). The expression level of eGFP was normalized with 𝛽-actin. Data represents 






6. THERAPEUTIC BRAIN-PENETRATING CISPLATIN 
NANOPARTICLES REDUCE TOXICITY AND IMPROVE 
EFFICACY AGAINST MALIGNANT GLIOMA 
 
6.1. Introduction 
The introduction of orally administered temozolomide (TMZ), the current 
chemotherapeutic of choice for treatment of GBM, has resulted in only minor 
improvements in patient survival, despite its relative ability to cross the blood brain 
barrier (BBB) [4, 13]. The effectiveness of TMZ is diminished due to its rapid 
degradation in physiological conditions, low potency as an alkylating agent and 
development of tumor resistance [13, 15, 115]. Furthermore, TMZ has dose limiting 
systemic toxicities in the forms of myelosuppression and lymphopenia [14-16]. For these 
reasons, current efforts are focused on identifying additional chemotherapeutics that may 
supplant or be used in combination with TMZ as a treatment for GBM [116]. 
Cis-diamminedichloroplatinum (Cisplatin, CDDP) is a highly potent anti-cancer 
drug and has demonstrated success in treating neoplasms such as testicular, ovarian, 
bladder and lung cancers [117]. Additionally, systemic CDDP has been widely adopted 
as an adjuvant therapy for several brain tumors in pediatric patients, such as 
neuroblastoma and medulloblastoma [118]. However, adult GBM clinical trials that 
employ systemic administration of CDDP have demonstrated limited success due to the 
high occurrence of nephrotoxicity and neurotoxicity manifesting even at sub-therapeutic 
levels [119-122]. Thus, clinical trials for GBM have administered alternative platinum 
agents (i.e. carboplatin) that exhibit reduced toxicities but are also less efficacious [123]. 




then it may be a highly relevant chemotherapeutic for achieving improved therapeutic 
outcome in patients with GBM. 
Local administration of chemotherapeutics is clinically applied as an adjuvant 
therapy for the treatment of GBM [124], and is an excellent strategy for avoiding off-site 
toxicities [31]. Intracerebral infusion of CDDP at low doses has been safely conducted in 
humans to treat malignant glioma [125, 126], but therapeutic benefit has not observed, 
indicating that higher chemotherapeutic concentrations was required. Recent preclinical 
studies have achieved promising results following intratumoral administration of CDDP 
[127, 128] but the local, neurotoxic effects of CDDP remain a significant limitation to 
direct intracranial administration [128, 129]. Nanotechnology enables the design of drug-
delivery platforms that provide controlled release of chemotherapeutics and can lead to 
simultaneous enhancement of therapeutic efficacy while ensuring safety of the treatment 
[117, 124]. Combined with local administration, this approach offers the opportunity to 
achieve sustained therapeutic levels of CDDP in the tumor with reduced off-target 
effects. 
Despite the aforementioned advantages, locally administered drug delivery 
platforms attain limited efficacy due to their inability to escape from the point of 
administration and distribute throughout the tumor tissue [32]. As previously stated in 
this thesis, only NP with diameters smaller than the average mesh-spacing of the brain 
ECM and shielded with a bio-inert coating are able to diffuse within the brain 
parenchyma [2]. Rational NP design [2, 130] and convection enhanced delivery (CED) 
[29, 33], are being investigated to overcome this barrier but only recently have efforts 




manually administered into the tumor, brain-penetrating nanoparticles (BPN) loaded with 
paclitaxel were highly effective at delaying the growth rate of an orthotopically implanted 
rodent gliosarcoma but failed to achieve a substantial improvement in survival [2, 40]. 
Here, we hypothesize that the intracranial delivery of a CDDP-loaded BPN (CDDP-BPN) 
combined with CED may provide widespread homogeneous delivery of CDDP 
throughout the tumor and lead to improved therapeutic efficacy. 
We have designed a sub-100 nm poly-aspartic acid (PAA)-based NP that 
possesses a dense surface layer of polyethylene glycol (PEG) and a high CDDP content 
that can be released in a sustained manner. This NP is able to diffuse in healthy and 
tumor rat brain tissue ex vivo and demonstrate improved distribution within the brain 
parenchyma in vivo. When manually administered, these BPN delayed the growth rate of 
a highly aggressive rat glioma as compared to conventionally designed NP. Furthermore, 
when delivered using CED, these CDDP-BPN significantly extended the survival of 
orthotopic GBM-bearing rodents. Therefore, administering CDDP-BPN using CED 
addresses the toxicity limitations of CDDP and represents a promising therapeutic 
strategy for the treatment of malignant gliomas. 
 
6.2. Materials and Methods 
6.2.1. Peptide conjugation, labeling, and NP synthesis 
PAA (MW: 27kDa, Alamanda Polymers, Huntsville, AL) was reacted with PEG (MW: 
5kDa, Creative PEGworks, Winston Salem, NC) at a 1:10 molar ratio with the addition of 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Invitrogen, Carlsbad, CA) at 




(MES Buffer, pH 5.0, Sigma Aldrich, St. Louis, MO). The reaction was carried out for 72 
h at room temperature followed by dialysis against deionized water using a 20kDa 
MWCO cassette (Spectrum Lab, Rancho Dominguez, CA) for 120 h. The solution was 
then lyophilized to obtain the PEG-PAA polypeptide which was then stored at -20
o
C until 
use. The PAA:PEG ratio was confirmed through nuclear magnetic resonance (NMR) to 
be ~1:10. 
1
H NMR (500 MHz, D2O): δ  2.70-2.80 (br, CHCH2COOH) 3.55-3.75 (br, 
CH2CH2O), 4.40-4.55 (br, NHCHCH2). Immediately prior to NP formulation, the 
lyophilized polymers were dissolved in ultrapure distilled water.  
Fluorescent labeling dye AlexaFluor 555 and AlexaFluor 647 carboxylic acid, 
succinimidyl ester (AF555 and AF647, Molecular Probes, Eugene, OR) was conjugated 
to PAA-PEG and PAA polypeptide respectively by dissolving in 200 mM borate buffer 
(pH 8.2) and reacting for 72 h at room temperature. The solution was dialyzed against 
deionized water using a 20kDa MWCO cassette (Spectrum Lab) for 120 h followed by 




CDDP-UPN and CDDP-BPN were formulated using the following protocol. For 
the CDDP-UPN, 7.5 mM of CDDP (Sigma Aldrich) was mixed with 5 mM of aspartic 
acid in RNAse free water for 72 h at room temperature. For CDDP-BPN, 5 mM of CDDP 
was mixed with a 5 mM of aspartic acid (9:1 ratio of PEG-PAA:PAA) in RNAse free 
water for 72 h at room temperature. Particles were then collected using filters (Amicon 
Ultra, 100kDa MWCO; Millipore, Billerica, MA) by centrifuging at 1000 g for 10 min 





6.2.2. Physicochemical characteristics and in vitro release characterization 
Physicochemical characteristics of NP were determined using a Zetasizer NanoZS 
(Malvern Instruments, Southborough, MA). All particles were diluted in 10 mM NaCl 
(diluted from phosphate buffered saline) and dynamic light scattering was employed to 
determine the hydrodynamic diameter and PDI at a backscattering angle of 173
o
. The 
surface charge (𝜁-potential) of the particles was determined through Laser Doppler 
Anemometry. Quantification of CDDP within the NP was conducted through flameless 
atomic absorbance spectroscopy (AAS) (Perkin Elmer, Waltham, MA) and loading was 
calculated as the % mass of CDDP in the total sample. NP imaging was conducted using 
a Hitachi H7600 transmission electron microscope (TEM, Hitachi, Japan). 
To determine CDDP release, CDDP-UPN or CDDP-BPN were dispersed in 1 mL 
of ACSF (Harvard Apparatus, Holliston, MA) within a 100kDa MWCO dialysis 
membrane (Spectrum Lab). The chamber was then placed in a 13 mL ACSF sink and 
shaken at 37
o
C. At specific timepoints, 1 mL of the sink was removed and replaced with 
1 mL of fresh ACSF. Samples were then diluted accordingly in ACSF and quantified 
using AAS.  
 
6.2.3. Ex vivo NP tracking in healthy and tumor rodent brain tissue 
Healthy or tumor rat brain tissue slices were prepared according to a slightly modified 
protocol of a previously publication [2]. F98 tumor bearing rats were sacrificed 12 days 
after tumor inoculation (1x10
5 
cells) to ensure a significantly large tumor bulk for 
investigation. Healthy or tumor brain tissue was sliced into 1.5 mm thick slices using a 




microscopy chambers. Half a microliter of fluorescently labeled particles was injected at 
a depth of 1 mm into the cerebral cortex using a 10 µL Hamilton Neuros Syringe 
(Hamilton, Reno, NV). The chambers were sealed using a coverslip to minimize 
convective bulk flow so that particle movement could be fully attributed to Brownian 
diffusion. The transport rate of particles was calculated by analyzing the particle 
trajectories in brain tissue slices as described previously [2]. The particle trajectories 
were recorded as 20 s movies at an exposure of 66 ms using an EMCCD camera (Evolve 
512; Photometrics, Tuscon, AZ) mounted on an inverted epifluorescence microscope 
(Axio Observer D1, Carl Zeiss, Hertfordshire, UK) equipped with a 100x oil-immersion 
objective. N = 3 rat brain tissue specimens were used for each particle type. MSD of 
particles were calculated and compared at a time scale of 𝜏 = 1 s. Theoretical MSD of NP 
in ACSF was calculated using theoretical Stokes-Einstein equation and the mean particle 
diameter calculated through dynamic light scattering.  
 
6.2.4. In vivo NP distribution following manual or CED administration 
Fluorescently labeled CDDP-UPN or CDDP-BPN (12 µg of CDDP) were loaded in a 50 
µL Hamilton Neuros Syringe (Hamilton) and co-injected at a ratio of 1:1 into the striatum 
of Male Sprague Dawley Rats weighing 200-220g. A burr hole was drilled 3 mm lateral 
and 1 mm posterior to the bregma. For a manual injection, the catheter was lowered to a 
depth of 4.0 mm and raised up 0.5 mm. The NP mixture was manually administered at a 
rate of 2 µL/min for a total of 10 µL. Catheter was then withdrawn at a rate of 1 mm/min. 
For CED, the catheter was vertically mounted on a Chemyx Nanojet Injector Module 




Wood Dale, Il). The catheter tip was lowered to a depth of 3.5 mm and NP were infused 
at a rate of 0.33 µL/min followed by catheter withdrawal at a rate of 1 mm/min. Animals 
were sacrificed 1 h post-administration and the brains were removed and immediately 
frozen on dry ice. Tissues were cryosectioned (Leica CM 3050S, Leica Biosystems, 
Buffalo Grove, Il) into 100 µm coronal slices and imaged using a Zeiss confocal 710 
laser scanning microscope in the DS Red (AF555, CDDP-UPN), and Cy5 (AF647, 
CDDP-BPN) channels. As previously conducted [132], brain slice images were 
quantified for fluorescent distribution of NP within the striatum using a custom 
MATLAB script which thresholded the images at 10% of the maximum intensity. 
Fluorescent distribution of NP in the ventricles or white matter tracts (WMT) were 
avoided and not included in the quantification. The area of distribution calculated from 
each slice was multiplied by the slice thickness of 100 m and summated across all 
images to obtain a total volume of distribution. 
 
6.2.5. CDDP dose escalation for in vivo toxicity 
A 10 µL solution of CDDP-FD (12 µg and 24 µg) or CDDP-BPN (12 µg, 24 µg, and 48 
µg) was administered intracranially using a manual injection. For 5 days following 
CDDP administration, the rats were evaluated 3 times a day for physical deficiencies and 
subsequently once every day. Weights were recorded every other day and rats were 
sacrificed when necessary due to clinical presentation of symptoms. The study was 





6.2.6. In vivo F98 tumor inoculation 
Female Fischer F344 rats weighing 100-140 g were anesthetized with a mixture of 
ketamine-xylazine as previously described [133] and inoculated with luminscence 
expressing F98 glioma cells (1x10
5 
cells). Briefly, a sagittal incision was made to expose 
the skull followed by the drilling of a burr hole 1 mm posterior and 3 mm lateral to the 
bregma. A 10 µL solution of F98 glioma cells was administered into the striatum at a 
depth of 3.5 mm. The head was then closed using biodegradable sutures (Polysorb™ 
Braided Absorbable Sutures 5-0, Covidien, Mundelein, Il) and Bacitracin was applied 
generously. 
 
6.2.7. In vivo bioluminescence monitoring of tumor progression 
Rat weights were measured every other day and optical imaging of the tumor was 
conducted every 3 days following treatment. Briefly, rats were injected intraperitoneally 
with 8 mg/mL luciferin (Sigma Aldrich) and were imaged 10 min later. The rats were 
subjected to a continuous flow of isoflurane and imaged using IVIS optical imaging for 
the presence of luciferase expressing tumor cells. Monitoring of tumor growth was 
terminated when the first normal saline treated rat was sacrificed due to clinical 
symptoms attributed to tumor progression. 
 
6.2.8. Treatment of F98 glioma-bearing rodents 
At the predetermined days post-inoculation, rats were randomized into treatment groups. 
The burr hole was re-accessed and 10 µL of the therapeutic solution (12 µg of CDDP) 




cages and continuously monitored for deficiencies. For animals undergoing radiotherapy, 
rodents were anesthetized and a focused radiation beam (2 Gy/min for a total of 15 Gy) 
was administered on the ipsilateral hemisphere where the tumor was implanted. 
 
6.2.8. Efficacy involving human xenograft GBM 
On Day 0, nude mice were inoculated with 10
5
 luciferase expressing GBM-1 human 
xenograft cells in collaboration with Dr. Eberhart’s lab. The striatum was similarly 
targeted in mice (as was conducted in rats) at the following coordinates: 0 mm 
anterior/posterior and 2 mm lateral to bregma. Syringe was lowered to 2.5 mm prior to 
administration of the tumor cell solution (2 µL).Tumors were allowed to grow for 30 
days and tumors were luminescently imaged to confirm establishment of GBM-1 
xenografts. Briefly, animals were injected intraperitoneally with 15 mg/mL luciferin and 
8 minutes later, imaged using IVIS optical imaging. Animals were randomized into two 
treatment groups. On Day 31, the burr hole was accessed in the animals that were to be 
treated with CDDP-BPN. 2 µL of a 0.9 mg/mL CDDP-BPN solution was administered at 
a rate of 0.2 uL/min at the same coordinates as before. The animal’s heads were sutured, 
bacitracin was generously applied on the wound, and mice were returned to their cages. 
 
6.2.10. Monitoring of animal survival 
Animals were monitored for deficiencies daily and weighed every other day. Animals 
were sacrificed when deemed humanely necessary in a blinded manner according to 





6.2.11. Statistical analysis  
Statistical significance testing between two groups was conducted using a two-sample t-
test. Significance was considered at p < 0.05. Comparisons between more than two 
groups included a one-way ANOVA test followed by a Games Howell test. Kaplan Meier 
analysis was conducted using a Log-Rank test. Statistical significance was considered at 
p < 0.05.  
 
6.3. Results 
6.3.1. NP characterization 
We engineered conventional un-PEGylated CDDP NPs (CDDP-UPN) and highly 
PEGylated CDDP-BPN with diameters smaller than the brain pore size [2] (Table 6.1). 
CDDP-BPN was uniformly formed with low polydispersity index (PDI) (0.11 ± 0.02) and 
near neutral surface charge as indicated by 𝜁-potential (-8.6 ± 1.1 mV), whereas the 
similarly sized CDDP-UPN exhibited higher PDI (0.2 ± 0.01) and highly anionic surface 
charge (-35 ± 2.0 mV) as expected from the carboxyl side groups of PAA. Both NP 
formulations were spherical in shape (Figure 6.1A, B) and were able to encapsulate a 
high concentration of CDDP (w/w) with a higher drug quantity loaded in a CDDP-BPN 
(19.5  1.4%) as compared to the CDDP-UPN (9.5  1.6%) (Table 6.1). Controlled, 
linear CDDP release kinetics were observed with both formulations over the course of 24 





6.3.2. Ex vivo diffusion of CDDP-NP in brain tissue 
To determine whether the densely PEGylated NP can diffuse within the tissue 
parenchyma, we administered fluorescently labeled CDDP-UPN and CDDP-BPN 
formulations in freshly excised healthy rat brain or rat tumor tissues, tracked the 
individual particle trajectories, and quantified their mean square displacements (MSD). In 
healthy rat brain tissue, the dense surface PEG coating significantly improved the ability 
of CDDP-BPN to rapidly diffuse within the rat brain parenchyma. Representative NP 
trajectories over 20 s demonstrated unhindered diffusion of CDDP-BPN that traversed 
over greater distances compared to CDDP-UPN (Figure 6.2A, C). We quantified the 
MSD using multiple particle tracking (MPT). At a timescale of 𝜏 = 1 s, the ensemble-
averaged MSD (<MSD>) of the CDDP-UPN was 17,100-fold lower in healthy rat brain 
tissue than in ACSF, as opposed to the <MSD> of CDDP-BPN, which was only 285-fold 
lower (Table 6.1). Therefore, CDDP-BPN were able to diffuse 60-fold faster than CDDP-
UPN in healthy rat brain tissue. We similarly characterized ex vivo NP diffusion in F98 
tumor tissue through MPT (Figure 6.2B, D) and found that at 𝜏 = 1 s, the <MSD> of 
CDDP-BPN was only 115-fold slower than in ACSF whereas CDDP-UPN was 1,000-
fold slower than in ACSF (Table 6.1), corresponding to a 9-fold difference between NP 
types (p < 0.05) (Figure 6.2D). 
 
6.3.3. Improved in vivo distribution of CDDP-BPN when administered with CED 
To verify our ex vivo findings, we manually co-administered fluorescently labeled 
CDDP-BPN and CDDP-UPN in vivo into the rat striatum and investigated the respective 




the striatum is improved 14-fold as compared to Vd of CDDP-UPN (Figure 6.3A, C). We 
further co-administered CDDP-BPN and CDDP-UPN using CED to determine whether 
the pressure-driven flow could improve NP Vd. CDDP-BPN achieved homogeneous 
distribution throughout the striatum (Figure 6.3B, C) with a 6.5-fold enhancement in Vd 
as compared to its administration using a manual injection (Figure 6.3C). Similarly, the 
Vd of CDDP-UPN was also enhanced, albeit only by a factor of 3. Thus, this corresponds 
to a 29-fold higher Vd of CDDP-BPN than CDDP-UPN when both are administered 
using CED (Figure 6.3C).  
 
6.3.4. CDDP-BPN significantly improves CDDP therapeutic index 
Given that CDDP-FD is highly toxic when administered into the brain [129], we 
next evaluated whether the controlled release of CDDP from BPN provided an improved 
safety profile following intracranial administration. Healthy rats were treated with a 
manual administration of either CDDP-FD or CDDP-BPN at different CDDP doses 
administered in 10 L. Rats treated with CDDP-BPN at doses of 12 g (100% survival) 
and 24 g (80% survival) fared better than those treated with CDDP-FD at those same 
doses (47% survival and 23% survival, respectively) (Figure 6.4A). Furthermore, 40% of 
rats treated with 48 g CDDP-BPN were long-term survivors, representing an 
improvement in CDDP tolerability over those treated with CDDP-FD at half that dose. Of 
note, a dose of 48 g of CDDP-FD could not be tested due to the limited solubility of 
CDDP in water. We similarly utilized CED to administer CDDP-FD at 12 g (60% 
survival) and CDDP-BPN at 12 g (100% survival) and 24 g (80% survival), 




differences in animal tolerability to CDDP.  Thus, the CDDP-BPN formulation enables 
the administration of higher CDDP doses provided that the dose is well tolerated. Prior 
studies have safely administered 6 g of CDDP-FD intracranially [129]. We found that 
the maximum tolerable dose (MTD) of intracranially administered CDDP when delivered 
in CDDP-BPN is 2-fold higher at 12 g (Figure 6.4A, B).  
 
6.3.5. CDDP-BPN delays tumor progression following manual administration 
We next evaluated the ability of CDDP-BPN (12 g of CDDP) to delay tumor 
growth rate compared to CDDP-FD, CDDP-UPN, and normal saline (NS) following 
intracranial administration into rats bearing a high inoculum of orthotopically implanted 
F98 rat glioma cells. In accordance with our findings in the neurotoxicity study (Figure 
6.4 A, B), the CDDP-FD treatment was prohibitive as the majority (>50%) of rats 
demonstrated seizure-like symptoms within 5 days following the treatment. Continuous 
monitoring of tumor size through optical imaging of tumor bioluminescence revealed a 
statistically significant reduction in the rate of tumor growth in the CDDP-BPN treated 
group on Days 7 and 10 compared to groups treated with saline or CDDP-UPN (p < 0.05) 
(Figure 6.5B, C). The tumor growth rates were similar between the CDDP-UPN and 
saline-treated groups, suggesting that CDDP-UPN failed to provide a therapeutic benefit. 
In good agreement with previously documented F98 tumor inoculations [133], saline-
treated rats presented with symptoms of significant lethargy and weakness on Day 12 and 





6.3.6. Improved survival of animals treated with CED administered CDDP-BPN 
Given that a manual injection of CDDP-BPN achieved significant tumor growth 
delay, we further evaluated efficacy of CDDP-BPN and CDDP-UPN against F98 glioma 
when administered using CED. Animals that were treated with saline had a median 
survival of 28 days whereas manually administered CDDP-UPN and CDDP-BPN 
achieved a median survival of 37 and 42 days respectively (Figure 6.6B, C). In 
combination with CED, the therapeutic efficacy of CDDP-UPN did not significantly 
improve (median = 40 days), although a minor population (30%) exhibited extended 
survival (greater than 100 days). CDDP-BPN delivered using CED achieved significantly 
improved survival (p < 0.05) as compared to all other treatment groups (Figure 6.6B, C). 
The majority of animals (80%) remained alive at day 100 and were deemed long-term 
survivors. No signs of F98 tumor was evident in CED administered CDDP-BPN treated 
rodents (Figure 6.7). 
A second efficacy study was initiated to interrogate the efficacy of CDDP-BPN 
upon treatment of larger sized tumors. Therefore, we inoculated 10
5 
F98 glioma cells and 
withheld CDDP-BPN treatment until 3 days, 6 days, or 9 days post-inoculation (Figure 
6.8A). Regardless of treatment day, animals that received CDDP-BPN exhibited 
improved survival (p < 0.05) as compared to the non-treated group. However, no 
significant survival differences were observed between animals treated on Day 3, Day 6, 
and Day 9. 
A third efficacy study was conducted to investigate whether the addition of 
radiotherapy, an essential component in the current treatment regimen for human GBM, 






F98 glioma cells and treated with CDDP-FD (6 g) and CDDP-BPN (24 g) on Day 3, 
followed by radiotherapy 1 day later. Radiotherapy alone improved the median survival 
time (MST) to 28 days, a significant improvement as compared to non-treated animals 
(MST = 20 days). Intriguingly, all 4 treatment groups that received CDDP (either FD or 
BPN) demonstrated some percentage of cures and there was no statistical significance 
between these 4 groups. CDDP-FD and CDDP-BPN treated animals exhibited the best 
survival with 70% and 60% of those animals exhibiting long term survival, respectively. 
However, the combination of radiotherapy with CDDP-FD and CDDP-BPN appeared to 
have worsened their outcome.  
 
6.3.7. Efficacy of CDDP-BPN against human xenograft GBM-1 cells 
Having observed promising efficacy results using CDDP-BPN against aggressive rodent 
models of GBM, we next wanted to determine the therapeutic efficacy of this 
nanoparticle against alternative GBM models (i.e. human xenografts). The GBM-1 in 
vivo model, conducted in collaboration with Dr. Eberhart’s group, establishes at a slower 
rate in comparison to the rodent models of GBM (i.e. F98 and 9L). Thus, we treated 31 
days post-inoculation and observed for long term survival. However, both in vivo 
luminescent imaging of tumor size (Figure 6.10b) and overall survival (Figure 6.10c) did 







Improving the distribution of a chemotherapeutic within the tumor parenchyma following 
intracranial administration is essential for achieving improved therapeutic outcome [20, 
33], but current drug delivery strategies have been unable to effectively address this 
requirement. For example, small molecule drugs administered directly into the brain fail 
to distribute as they are rapidly metabolized or eliminated [20] . Conventionally designed 
NP avoid rapid clearance but they remain largely immobilized within the tumor 
extracellular space in the immediate vicinity of the point of administration [25, 26]. We 
methodically engineered CDDP-BPN and tailored its physicochemical characteristics 
(sub-100 nm, near neutral surface charge) to allow for homogeneous, widespread 
distribution throughout the tumor parenchyma [2, 20, 27]. These densely PEGylated 
CDDP-BPN can deliver higher concentrations of the chemotherapeutic in a sustained 
manner to a larger population of infiltrating tumor cells, thereby leading to decreased 
rates of glioma recurrence and improved therapeutic outcome. 
The effects of PEG coating on the NP surface have been well-documented and 
shown to provide several benefits including a monodisperse NP population as well as 
improved particle condensation and stability [99]. In good agreement with prior findings, 
the inclusion of a high density PEG yielded uniformly small CDDP NP with a near 
neutral surface charge that can rapidly diffuse through healthy [2] and tumor brain 
parenchyma [27]. However, effective CDDP complexation into a PAA-based NP is 
dependent on the number of available carboxyl groups for the formation of coordination 
bonds [134]. Hence, we anticipated that the conjugation of a large number of PEG chains 




previously described by our lab to improve NP condensation [135], a minor wt% (10%) 
of non-PEGylated PAA was incorporated into the CDDP-BPN formulation. This 
provides additional carboxyl groups that bind with CDDP, thereby improving the CDDP 
loading without compromising the dense PEG layer on the surface of the NP. A suitable 
dense PEG layer on the NP surface was further confirmed by the near neutral surface 𝜁-
potential and the ability of the NP to rapidly diffuse ex vivo and in vivo within rat brain 
tissues. 
CDDP is known for its high anti-tumor potency, but its applicability for treating 
human GBM has been limited by significant toxicities when locally or systemically 
administered [117]. Controlling the release kinetics of CDDP has been shown to alleviate 
its toxicities in a variety of tumor models by preventing the exposure of cytotoxic 
concentrations to the surrounding healthy tissues [136-139]. Here, both CDDP-UPN and 
CDDP-BPN formulations exhibited linear release of CDDP over 24 h in ACSF, triggered 
by the presence of chloride, calcium, and magnesium ions that compete with CDDP for 
carboxylate coordinate bonds [140]. We found that controlled release of CDDP 
significantly reduces local neurotoxicity compared to CDDP-FD administration in both 
healthy and tumor-bearing rats. Thus, CDDP-BPN enables the administration of 
significantly higher doses of the chemotherapeutic that can further lead to improved 
therapeutic efficacy. Given that the high incidence of CDDP-associated toxicities has led 
to the early termination of many clinical trials, the improved safety profile of CDDP 
when delivered in a BPN represents a significant improvement in the relevance of CDDP 




Local administration of chemotherapeutics has the potential to achieve high 
concentrations of therapeutics in the tumor and has achieved significant clinical success 
as demonstrated by the Gliadel® wafer [30, 142], but limited diffusion of the drug from 
the implantation site has minimized its therapeutic efficacy [143]. Here, we characterized 
the distribution of CDDP NP using two, well-detailed strategies: 1) manual injection [29] 
and 2) CED [29, 33]. When administered using a manual injection, CDDP-BPN achieved 
higher Vd within the rodent striatum as compared to the Vd of conventionally designed 
CDDP-UPN but a high percentage of CDDP-BPN was found in the WMT, likely due to 
fluid backflow that resulted from the rapid injection. When administered using CED, 
CDDP-BPN was able to harness the advantages of the pressure-driven fluid flow 
provided by CED and achieved more homogeneous and significantly higher Vd within 
the striatum while minimizing its presence in white matter tracts (WMT). This establishes 
that both appropriate NP design and method of delivery are important considerations as 
only the combination of CDDP-BPN delivered using CED significantly enhanced 
survival of tumor-bearing rodents. 
Radiotherapy has been shown to be synergistic in preclinical studies when 
combined with the platinum chemotherapeutics against orthotopic rodent GBM [127, 
144]. Thus, we investigated the combination therapy of CDDP-BPN and CDDP-FD with 
radiotherapy (XRT) in hopes of further enhancing the survival efficacy of the treatment. 
In good agreement with previous studies, XRT alone significantly enhanced survival but 
we found that rodents treated with the combination of CDDP and XRT exhibited far 
decreased survival efficacy. We believe that toxicities may have come into play as all 




rodent deaths, indicating that the CDDP doses that were administered may have been too 
high. Thus, the addition of XRT may have further enhanced the toxicities. Future 
tailoring of the CDDP-FD and CDDP-BPN doses in combination with XRT must be 
conducted in order to fully understand whether the combination of CDDP-BPN and XRT 
are synergistic. However, we note that CDDP remains a highly promising treatment as a 
significant number of animals that survived CDDP-associated toxicities remained alive 
up to 120 days post-inoculation. 
In the clinical setting, CED has been widely employed in clinical trials for 
intracranial administration of therapeutics following tumor resection of patients 
diagnosed with high grade gliomas [145-147]. These studies were conducted under the 
notion that CED can achieve therapeutic distribution up to centimeters away from the 
administration site [148], but investigational studies following the failure of these clinical 
trials have revealed that the distribution remains poor and nonhomogeneous [6]. We 
demonstrate that CED of a CDDP-BPN can achieve widespread distribution within the 
rodent striatum, which leads to a significantly improved therapeutic outcome, as 
demonstrated by all 3 of our efficacy studies (Figures 6.6, 6.8, 6.9). Of note, CED of 
CDDP-UPN or manual administration of CDDP-BPN was not as efficacious as the CED 
administration of CDDP-BPN, emphasizing the importance of the combination of CED 
with a BPN. In light of these positive results, we admit that there remain further hurdles 
to overcome in evaluating this CDDP-BPN technology before clinical applications in 
humans can be started. Namely, further investigations involving human xenograft tumors 
as well as larger animal models will be required. Nevertheless, the translational 




similar, peptide-based CDDP NP which has demonstrated promising Phase I/II results 
and is currently under investigation in a Phase III clinical trial for pancreatic cancer 
[149]. With our findings to date, we anticipate that local, intratumoral administration of 
CDDP-BPN using CED may be a promising adjuvant therapy for patients diagnosed with 
high grade gliomas. 
 
6.5. Conclusion 
The development of a CDDP-BPN addresses two major concerns pertaining to the use of 
CDDP as a chemotherapeutic agent and enables us to harness the potency of CDDP for 
the treatment of GBM. Namely, administering CDDP-BPN using CED (1) reduces the 
inherent toxicities associated with CDDP and (2) delivers high concentrations of CDDP 
throughout the tumor bulk, yielding improved therapeutic efficacy. As a therapeutic 
platform, we anticipate that CDDP-BPN delivered using CED can be rapidly combined 
with additional adjuvant therapies such as radiotherapy that may further improve the 





Table 6.1: Characterization of the size, 𝜁-potential, and MSDs of CDDP NP in normal and tumor rat brain 
tissue compared to their theoretical MSDs in ACSF. Size and ζ-potential were measured in ACSF at pH 


















CDDP-UPN 65 ± 3 -35 ± 2 0.20 ± 0.01  9.5 ± 1.6% 17,000 1,000 







Figure 6.1: In vitro characterization of CDDP NP. (A, B) TEM imaging of CDDP-UPN and 
CDDP-BPN formulations. Scale bar = 500nm. (C) Quantified in vitro release kinetics in ACSF 
(pH 7.0) demonstrating similar, linear release of CDDP from both CDDP-UPN and CDDP-





Figure 6.2: Particle diffusion in healthy rodent brain tissue. (A-D) Representative 
trajectories of (A, B) CDDP-BPN and (C, D) CDDP-UPN in healthy and rodent brain 
tumor tissue over 20 s of tracking. (E) <MSD> of CDDP-BPN and CDDP-UPN at a 
timescale of 𝝉 = 1 s in at least N=3 ex vivo healthy or tumor rodent brain tissue 
samples. Greater than 100 NP were tracked per sample. * p < 0.05 denotes statistically 





Figure 6.3: Distribution of CDDP-UPN and BPN in vivo. (A-B) Representative 
images of a 10 L co-administration of CDDP-UPN (green) and CDDP-BPN (red) into 
the rodent striatum using (A) a manual injection or (B) CED. NP overlay depicted as 
yellow. N ≥ 3 for each administration. Scale bar = 1 mm. (C) Vd of CDDP-BPN and 
CDDP-UPN following manual or CED administration. Calculations were conducted 
using image-based MATLAB quantification. * p < 0.05 denotes statistical significance 






Figure 6.4: In vivo CDDP toxicity: (A) Kaplan Meier survival curve of CDDP-FD and CDDP-
BPN (N ≥ 5 in each group) administered in healthy rodents using a manual injection. * p < 0.05 
for both 24 ug FD and 48 ug CDDP-BPN groups as compared to 12 ug CDDP-BPN group that 
experienced no deaths from the treatment.  (B) Kaplan Meier survival curve of CDDP-FD and 




Figure 6.5: In vivo tumor growth delay: (A) Tumor inoculation and CDDP treatment scheme for 
monitoring tumor growth delay. (B) Bioluminescent monitoring of F98 tumor size following a 
1x10
5
 inoculation. Rodents were treated with 10 L of Saline, CDDP-FD, CDDP-UPN, or CDDP-
BPN. Delayed tumor growth occurred at Day 7 and 10 post-inoculation when rodents were treated 
with CDDP-BPN. * p < 0.05 significance between CDDP-BPN and both Saline/CDDP-UPN 







Figure 6.6: In vivo survival efficacy. (A) Tumor inoculation and CDDP treatment 
scheme for investigating long term survival. (B, C) Rats inoculated with 10
3
 F98 glioma 
cells were treated on Day 7 following inoculation with 1) Saline, 2) Manual injection of 
CDDP-FD, 3) Manual injection of CDDP-UPN, 4) Manual injection of CDDP-BPN, 5) 
CED of CED-FD, 6) CED of CDDP-UPN, and 7) CED of CDDP-BPN. Kaplan Meier 
survival curve depicts significantly improved (p < 0.05) long term survival of the 
combination of CED administered CDDP-BPN as compared to all other treatment 
groups. # indicates the presence of long term survivors (greater than 100 days) in the 








Fig 6.7: Coronal slice of H&E stained rodent brains following tumor inoculation 
and treatment. At their median survival dates, large F98 tumors are seen in the striatum 
of (A) non-treated and (B) CED administered CDDP-UPN treated rodents. (D, E) High 
magnification images illustrate the presence of pseudopalisading fronts and necrotic 
cores that are characteristic of F98 tumors. (C) On the contrary, CED administered 
CDDP-BPN treated rodents show no remnants of F98 tumors upon their sacrifice at 100 









Fig 6.8: Time dependent efficacy of CDDP-BPN against orthotopic 10
5
 inoculation of F98 
glioma cells in rats. (A) Tumor inoculation and CDDP treatment scheme for investigating long 
term survival. (B, C) F98 glioma bearing rats were treated with CDDP-BPN on Day 3, Day 6, or 
Day 9 using CED. Kaplan Meier survival curve depicts improved (p < 0.05) long term survival of 
CED administered CDDP-BPN as compared to no treatment. (C) Statistics and breakdown of 
individual treatment conditions. (D, E, F) Histological images of F98 glioma tumors on the three 








Fig 6.9: Efficacy of CDDP-BPN in combination with radiotherapy against orthotopic 10
5
 
inoculation of F98 glioma cells in rats. (A) Tumor inoculation and treatment scheme (B, C) Kaplan 
Meier survival curve depicts improved (p < 0.05) long term survival of CDDP treated animals (both FD 
and BPN) as compared to radiotherapy only and no treatment animals. (C) Statistics and breakdown of 











Fig 6.10: Efficacy of CDDP-BPN against human xenograft GBM. (A) Tumor inoculation and CDDP 
treatment scheme for investigating long term survival of GBM-1 bearing nude mice. (B) Luminescent 
imaging of GBM-1 cells at day 60 following tumor inoculation. Average luminescence was quantified 
and no statistically significant difference was observed. (C) Kaplan Meier survival curve depicting 







7. IMPROVING CED THROUGH THE ADMINISTRATION OF 




CED is an effective delivery strategy to circumvent the blood brain barrier (BBB) and 
can theoretically achieve widespread NP distribution by harnessing a pressure driven 
bulk flow [20, 36, 150]. However, recent advances in technological imaging have 
determined that administering a NP using CED still fails to achieve therapeutically 
favorable distribution [7]. Intracranially administered NP travel through the brain 
interstitium, which comprises two distinct spaces: the intercellular space (ICS) and 
perivascular space (PVS). NP distribution in the ICS is limited by hindrances imposed by 
the extracellular matrix (ECM) components [2]. Moreover, the preferable flow of NP 
through, and subsequent confinement within, the low resistance, fluid-filled PVS reduces 
their ability to reach the target cells [7, 151]. These revelations have shed light on prior 
terminated CED-based clinical trials that failed to meet their primary and secondary 
outcomes [5, 152] and have spurred the development of the next generation of NP 
systems optimized for CED [28, 29]. 
PVS are cerebrospinal fluid (CSF) filled canals surrounding large brain vessels 
and are responsible for the clearance of metabolites to maintain homeostasis in the brain 
[153]. When administered into the brain, NP encounter a higher resistance when traveling 
through the ICS than through the PVS [154]; therefore, significant quantities of infused 
NP have been visually confirmed to traffic through PVS [7, 8]. Once localized in the 
PVS, NP remain sequestered due to the glia limitans, the anatomical barrier that separates 




occurs following all available delivery strategies to the brain, including administrations 
using intranasal, intracisternal, or intrathecal routes [151, 156, 157]. Given that NP 
confinement in PVS has been suggested to lead to a reduction in therapeutic efficacy in 
clinical trials [8, 35], an effective strategy to reduce PVS sequestration is essential.  
We propose a delivery strategy that combines the delivery of a well-shielded NP 
with the osmotic modulation of the brain tissue in order to minimize the hindrances of the 
brain ECM and preferable NP accumulation in PVS. More specifically, we utilize a 
previously developed, non-adhesive probe NP [2], and locally administer it in a 
hyperosmolar, 3% saline infusate solution into the rodent striatum using CED. We 
demonstrate that these improvements can be extended to a similarly engineered, 
therapeutically relevant drug nanocarrier. The results gleaned from this mechanistic study 
may be adapted to improve the clinical relevance of CED and must be further considered 
in future attempts at therapeutic delivery to the brain. 
 
7.2. Materials and Methods 
7.2.1. NP characterization in solutions of varying osmolarities 
To test NP stability, the particles were diluted 200-fold in the following infusate 
solutions: water, saline (0.9%, 3%) and mannitol (10%, 25%) and allowed to incubate for 
15 minutes at room temperature. NPs were then sized again using dynamic light 





7.2.2. Preparation of ex vivo tissues in solutions of varying osmolarities 
The brains from female CF-1 mice were harvested and MPT was conducted on NPs 
injected into 1.5 mm thick brain slices according to a slightly modified protocol of a 
previous publication [2]. Briefly, the harvested rodent brain was rinsed in chilled artificial 
spinal fluid and sliced at 1.5 mm intervals using a Zivic mouse brain mold (Zivic 
Instruments, Pittsburgh, PA). Individual brain slices were immersed in infusate solutions 
(water, 0.9% saline, 3% saline, 10% mannitol, or 25% mannitol) for 5 minutes. Brain 
slices were removed and mounted on a custom made well and 0.5 µL of fluorescently 
labeled PS-PEG NPs were injected into the cortex. A coverslip was glued on top of the 
specimen to prevent bulk flow in the tissue. 
 
7.2.3. Multiple particle tracking of PS-PEG NPs in treated ex vivo tissue slices 
The particle trajectories were recorded as 20 second movies at an exposure of 66 ms 
using an EMCCD camera (Evolve 512; Photometrics, Tuscon, AZ) mounted on an 
inverted epifluorescence microscope (Axio Observer D1, Zeiss; Thornwood, NY) 
equipped with a 100x oil-immersion objective (N.A., 1.3). NP mean squared 
displacements (MSD) were calculated based on a custom MATLAB NP tracking code 
and histograms of particle MSD were determined at a timescale of 𝜏 = 1 second. 
 
7.2.4. In vivo CED administration of non-adhesive NPs 
When preparing NPs for intracranial CED, stock PS-PEG and PS-COOH were each 
diluted 25-fold in water, 0.9% saline, 3% saline, 10% mannitol, or 25% mannitol and 




NPs were lyophilized overnight and resuspended at a concentration of 1 mg/mL in 0.9% 
saline or 3% saline for administration. 
Female CF-1 mice weighing 20-30 g in mass were anesthetized with a mixture of 
ketamine (75 mg/kg) and xylazine (7.5 mg/kg). For mice, a 2 cm sagittal incision was 
made on the head and a burr hole was made 2 mm lateral to the bregma. All NP solutions 
or infusate solutions were loaded into a 50 L Hamilton Neurosyringe with a 33 gauge 
syringe and set with a 1 mm step (Hamilton, Reno, NV). The syringe was vertically 
mounted on a Chemyx Nanojet Injector Module (Chemyx, Stafford, TX) which was held 
on a small animal stereotactic frame (Stoelting, Wood Dale, Il). The loaded syringe was 
lowered to a depth of 2.5 mm below the mouse dura and a total of 2 µL of the solution 
was administered over 10 minutes at a rate of 0.2 L/min. The cannula was allowed to sit 
for 5 minutes following the completion of infusion and was then withdrawn at a rate of 1 
mm/min. The animal was then sutured (Covidien, Mundelein, Il) and placed on a heating 
pad. 
 
7.2.5. Toxicity of infusate solutions 
Following intracranial administration of the various infusate solutions (no NP), CF-1 
mice were monitored for adverse signs of toxicity. Mice were sacrificed either 1 hour or 
72 hours post-administration. Brains were harvested and fixed in formalin for 24 hours 
followed by H&E staining analysis conducted by the Johns Hopkins Reference 
Histology. The injection point was identified by the tissue cavity imparted by the needle 
and the region immediately adjacent was imaged and evaluated for evidence of toxicity 





7.2.6. Tissue processing and staining for cellular nuclei or blood vessels 
Mice were co-injected with fluorescent dark red PS-PEG and red PS-COOH NPs. Tissues 
were harvested, post-fixed, and cryosliced at 10 m thickness at designated intervals 
from the coronal plane of injection (0 mm, 0.5 mm, 1.0 mm, and 1.5 mm). Tissues were 
mounted on glass slides and immersed in pepsin solution (Dako, Carpinteria, CA) at 37
o
 
C for 10 minutes. Slides were washed 3 times with PBS and blocked with blocking buffer 
composed of 5% normal goat serum (Sigma Aldrich, St. Louis, MO) and 1% bovine 
serum albumin (Sigma Aldrich, St. Louis, MO) in PBS for 1 hour at room temperature. 
Tissue slices were incubated with primary rabbit anti-mouse collagen IV antibody 
(Abcam ab6586, Cambridge, MA) diluted 1:250 in blocking buffer for 16 hours at 4
o 
C. 
Tissues were washed 3 times with PBS and incubated with a AF488 labeled goat anti-
rabbit secondary antibody (Life Technologies, Grand Island, NY) diluted 1:500 in 
blocking buffer for 1 hour at room temperature. Tissues were washed 3 times with PBS, 
and then incubated with DAPI (Life Technologies, Grand Island, NY) at a 1:1000 
dilution in PBS for 15 minutes at room temperature. Slides were washed 3 times with 
PBS and allowed to dry before mounting with Dako fluorescence mounting medium 
(Dako, Carpinteria, CA).  
 
7.2.7. Image-based quantification of NP distribution 
Animals were sacrificed 1 hour post-CED and the brains were fixed in formalin for 24 
hours and subsequently exposed to a 10%, 20%, and 30% sucrose gradient. Brains were 




Il). Distances ± 1.5 mm from the injection site were carefully obtained. Slices were fixed 
with Dako fluorescence mounting medium (Dako, Carpinteria, CA) and imaged using a 
Zeiss confocal 710 laser scanning microscope (Zeiss, Jena, Germany) in the GFP and 
Cy5 channels at 5x magnification. The presence of background fluorescence was 
determined by comparing to the striatum of the contralateral hemisphere with no 
injection. Brain slice images were quantified for fluorescent distribution of PS-PEG or 
PS-COOH NPs by running the confocal laser scanning microscope images through a 
custom MATLAB script which thresholded the images at 10% of the maximum intensity. 
Fluorescent distribution of NP in the ventricles or white matter tracts were avoided and 
not included in the quantification. The area of distribution calculated from each slice was 
multiplied by the slice thickness of 50 m and summated across all images to obtain a 
total volume of distribution. If a slice was lost during cryosection procedure, the area of 
distribution was taken as the average of the previous and following slices. Rarely was 
more than 1 slice lost from a brain specimen.  
 
7.2.8. Investigating NP presence in perivascular spaces 
Using a Zeiss confocal 710 laser scanning microscope, high resolution images (40x 
magnification) were taken at the designated intervals away from the main NP bulk and 
imaged for DAPI, collagen IV, PS-PEG, and PS-COOH. Images were derived from N=3 
mice specimen with at least N=3 images per animal. Presence of fluorescent PS-PEG and 
PS-COOH in PVS and ICS were qualitatively determined in all images. Presence of NP 




images, 2) consistent in 90% of all images, 3) consistent in 80% of all images, and 4) 
consistent in less than 20% of all images.  
 
7.2.9. Quantifying NP escape from perivascular spaces 
The lateral striate arteries in the rodent striatum were visually identified in the imaged 
slices by identifying elongated and flattened endothelial cells following a DAPI stain 
(Life Technologies, Grand Island, NY). Co-staining these endothelial cells with blood 
vessel basement membrane (Collagen IV) confirmed their lining of the striate artery. 
High resolution images using a Zeiss confocal 710 laser scanning microscope (40x 
magnification) were taken of PS-PEG and PS-COOH in the striate artery. To determine 
the extent of NP escape from PVS, images were processed through a custom MATLAB 
script. A line was drawn parallel along DAPI-stained endothelial cells that defined the 
striate artery. Fluorescent NPs intensities were averaged at 10 m intervals up to 100 m 
away from the striate artery. At least N=3 striate artery vessels were quantified in each 
condition. The percent NP coverage within the parenchymal ICS on each high resolution 
image (40x magnification) was calculated by using the custom MATLAB quantification 
script which thresholded the images at 10% of the maximum intensity. Flattened, DAPI-
stained endothelial cells that line the striate artery were used to delineate the PVS and the 
ICS and only detectable fluorescence throughout the ICS was quantified. At least N=3 





7.2.10. Statistical analysis  
Statistical testing between two groups were conducted using a two sample student t-test. 
If statistical comparisons involved more than two groups, testing was conducted with 
SPSS 18.0 software (IBM Inc.) using one-way ANOVA followed by Tukey honestly 
significant difference. Differences for t-test, ANOVA, and Tukey tests were considered 
statistically significant at p < 0.05. 
 
7.3. Results and Discussion 
7.3.1. Physicochemical characterization of NPs in varying solutions 
To determine the optimal infusate solution, the stability of PS-PEG and PS-COOH NPs 
were first characterized to ensure that the solution does not significantly impact their 
physicochemical characteristics or lead to aggregation. The sizes of both NPs remained 
unchanged in water and normal saline solutions. PS-COOH NPs aggregated in 3% saline 
concentrations and form substantially larger complexes, whereas PS-PEG NPs remained 
stable (Table 7.1). Both PS-PEG and PS-COOH NPs increased in size when immersed in 
higher mannitol concentration solutions (Table 7.1). 
 
7.3.2. Ex vivo NP diffusion in treated brain tissues 
For non-adhesive NP that are shielded from adhesive interactions with the brain ECM, 
the steric obstruction imposed by the ECM components constitutes the main limitation to 
efficient NP distribution [2, 77]. To overcome this barrier, prior studies have modulated 
the brain tissue to enlarge the pore sizes of the brain ECM and enhance therapeutic 




exposure of brain tissues to modestly hyperosmolar solutions (500 mOsmol/kg) increases 
the volume of ICS and minimizes the tissue’s cumulative resistance to NP diffusion 
[162]. Here, we sought to alter the pore sizes of the brain ECM by administering well-
shielded NP in infusate solutions of varying osmolarities. We selected hyperosmolar 
saline and mannitol solutions given that they have both been administered in clinical 
settings for reducing elevated intracranial pressure [163]. Furthermore, mannitol has been 
extensively investigated as a hyperosmolar infusate solution for CED of therapeutics in 
preclinical studies [158, 161, 164]. All infusate solutions were deemed safe following 
histological analysis of H&E stained mouse brains by a board-certified neuropathologist 
(Figure 7.1).  
To determine the changes in ECM pore sizes following exposure of the brain 
microenvironment to solutions of different osmolarities, we probed the pore sizes of the 
brain by using a previously established ex vivo technique [2, 19]. Of note, we ensured that 
the PS-PEG physicochemical characteristics were unaffected in the infusate solutions 
(Table 1) in order to accurately assess the effect of osmolarity on ECM pore size. 
Specifically, we incubated brain slices in hypo-osmolar water, iso-osmolar 0.9% saline, 
or hyperosmolar 3% saline and used MPT to quantify the diffusion of non-adhesive PS-
PEG probes [2]. At a timescale of 1 second, brain slices treated with hyperosmolar 3% 
saline yielded 1.5-fold higher NP MSD compared to brain slices incubated in normal 
saline (Figure 7.2A). This indicates that water drawn into ICS via the osmotic gradient 
generated by hyperosmolar saline has enlarged the ECM mesh spacing [159, 162], 
thereby reducing the steric hindrances imposed on PS-PEG traveling within the brain 




fold lower MSD values (Figure 7.2A). This reduced PS-PEG diffusivity is due to an 
increase in steric hindrances resulting from the engorging of cellular structures driven by 
water intake and subsequent reduction of ICS [159].  
 
7.3.3. Improved NP distribution when administered in hyperosmolar saline solutions 
To verify that the osmotic modulation of ICS observed ex vivo translates in vivo, we 
administered NP using CED in saline infusate solutions with varying osmolarities and 
determined their effect on the Vd of NP. We discovered that the Vd of non-adhesive PS-
PEG was positively correlated with the osmolarity of the infusate solution. However, 
higher osmolarity solutions did not significantly affect the Vd of PS-COOH (Figure 7.2B, 
C). This indicates that even when steric hindrances were minimized, adhesive 
interactions remained a dominating limitation for conventional NP. In fact, when infused 
in iso-osmolar and hyperosmolar solutions, Vd of PS-PEG was 5.8-fold and 6.8-fold 
higher than that of PS-COOH, respectively. In contrast, the Vd of PS-PEG and PS-
COOH were not significantly different when hypo-osmolar water was used as an infusate 
solution, suggesting that the elevated steric hindrances stemming from a reduction in 
ECM pore sizes serve as the dominant limitation to NP distribution. These observations 
emphasize the importance of simultaneously minimizing adhesive interactions and steric 
hindrances in order to maximize NP distribution in the brain interstitium following CED. 
 
7.3.4. Instability of NPs in mannitol yields no improvement in distribution 
It should be noted that CED of a non-adhesive NP in a hyperosmolar infusate solution is 




increasing the osmolarity of mannitol infusate solutions (from 10% to 25%) reduced PS-
PEG diffusivity in brain tissues ex vivo (Figure 7.3A) and distribution in vivo (Figure 
7.3B, C). Since the osmolarity is a colligative property independent of solute type, the 
contradictory findings are not likely due to any unique effect mannitol-based osmotic 
driven water flow. Rather, the results can be attributed to the marked increase in the size 
of PS-PEG in 25% mannitol infusate solution (Table 7.1), which offset the effect of 
enlarged ECM pores.  
 
7.3.5. Trafficking of NPs through perivascular spaces 
PVS, also known as Virchow Robin spaces in the brain, serve as a conduit for rapid flow 
of CSF into the brain from the subarachnoid space [165] and are responsible for the 
clearance of small metabolic molecules and waste products [153]. Numerous studies have 
demonstrated that the distribution of therapeutics at large distances away from the 
injection site takes place predominantly through the PVS [7, 8]. However, preferential 
trafficking and subsequent sequestration of intracranially administered NP in PVS [166] 
significantly reduce the available NP dose for treating target cells. Excessive therapeutic 
buildup within PVS has also resulted in toxic side effects to neighboring macrophages 
[26], undesired immune responses [8], and an overall reduction in therapeutic efficacy [7, 
8]. 
We hypothesize that the fraction of NP that distribute through the ICS as opposed 
to the PVS will be increased by modulating the brain tissue to reduce the resistance of the 
brain ECM to NP diffusion. We thus investigated the extent of NP trafficking within PVS 




confined in the PVS (Figure 7.4A-D, Table 7.2). However, when administered in normal 
saline, PS-PEG were found in the ICS up to 1.0 mm away from the plane of injection 
(Figure 7.4E-G, Table 7.2), and were localized only within PVS at 1.5 mm (Figure 7.4H, 
Table 7.2). Furthermore, PS-PEG infused in hyperosmolar 3% saline were found in both 
the ICS and PVS up to 1.5 mm away (Figure 7.4M, Table 7.2), suggesting that NP 
distribution in ICS may be enhanced by reducing ECM resistance. Reduced NP 
accumulation in the PVS and improved NP distribution throughout the ICS achieved by a 
hyperosmolar infusate solution offers a promising strategy to overcome a critical 
limitation of CED.  
Regardless of the infusate solution, PS-COOH were found solely associated with 
blood vessels (Figure 7.4A-M, Table 7.2). In fact, increasing saline concentration reduced 
the overall distance that PS-COOH trafficked through PVS. When infused in water and 
0.9% saline, PS-COOH were found in PVS up to 1.5 mm away from the plane of 
administration, whereas PS-COOH infused in 3% saline were located in PVS only up to 
0.5 mm away. The reduced distance can be attributed to the instability of PS-COOH in 
hyperosmolar saline (Table 7.1) as their rapid aggregation to sizes larger than 1 µm 
would significantly increase the steric hindrances encountered when trafficking through 
the PVS of arterioles that are sub-1 m in width [167].  
 
7.3.6. NP escape from perivascular spaces in lateral striate arteries 
Due to the intrinsically lower physical resistance of the PVS compared to that of ICS 
[156], NP trafficking in the PVS is inevitable regardless of administration parameters or 




through the glia limitans [168], a barrier formed by astrocytic endfeet that strictly 
delineates the PVS from the ICS with only ~20 nm intercellular openings [153, 155, 
169]. We hypothesize that by modulating the glia limitans using a hyperosmotic infusate 
solution, NP may be driven to escape PVS and distribute into the ICS. We investigated 
the lateral striate artery (Figure 7.5A), a large blood vessel structure previously shown to 
significantly sequester NP [7], to determine the extent of NP escape from this major 
artery. When administered in water, both PS-PEG and PS-COOH were confined to PVS 
(Figure 7.5B); less than 10% of PS-PEG or PS-COOH fluorescence was detected at a 
distance of 20 m from the blood vessel (Figure 7.5E). Similarly, when administered in 
0.9% saline, only 20% of both PS-PEG and PS-COOH fluorescence was observed at a 
distance of 20 m (Figure 7.5C, F), suggesting that even with non-adhesive coatings, NP 
fail to traverse the glia limitans into the ICS. But when particles were infused in 
hyperosmolar 3% saline, while PS-COOH were similarly sequestered in PVS, PS-PEG 
exhibited markedly improved escape from PVS (Figure 7.5D, G), indicating that a 
combination of a hyperosmolar solution with non-adhesive NP is necessary for PVS 
escape. In fact, 65% of PS-PEG fluorescence was observed at a distance of 20 m with 
20% of the fluorescence detectable even at 100 m. In these same high-resolution lateral 
striate artery images, we further quantified the percent coverage of fluorescent NP 
outside the PVS and within the brain ICS. Fluorescence of PS-PEG administered in 3% 
saline was detected across 30% of the ICS in the image, a significantly higher coverage 
(P < 0.05) as compared to PS-PEG administered in 0.9% saline (8% coverage) and water 




The migration of non-adhesive NP from the PVS into the ICS following infusion 
in a hyperosmolar solution can likely be attributed to the disruption and enlargement of 
the 20 nm astrocytic intercellular clefts, similar to our prior modulation of the brain ECM 
pores. Thus, larger NP can then escape into the ICS, but only if the NP surface is 
rendered non-adhesive. Regardless of the infusate solution, conventional NP are unable 
to reenter the brain ICS due to their adhesive nature that confines them to the PVS. To 
date, only small molecules (i.e. water, alexafluor dyes, small dextrans) and 20 nm adeno-
associated viruses (AAV) have been shown to partition from the PVS into the ICS [151, 
153] but here, we detail a strategy that enables the delivery of NP therapeutics as large as 
60 nm in diameter out of PVS, through the glia limitans, and into the ICS. 
PVS have been shown to play an important role in numerous neurological 
diseases. In Alzheimer’s disease, dysregulation of the PVS glymphatic system leads to 
widespread development of amyloid-β plaques [153, 170]. Similarly, PVS, as paths of 
least resistance, have been implicated in facilitating the migration of malignant gliomas 
throughout the brain [154, 171], thereby often leading to tumor recurrence. Hence, 
preferential NP trafficking through the PVS, followed by radial escape through the glia 
limitans and into the ICS, may be exploited to chase the propagation of neurological 
disease. 
 
7.3.7. Applicable findings to therapeutically relevant PLGA-NP system 
We sought to determine if our previous findings based on model NP probes can be 
translated to therapeutic NP derived from poly(lactic-co-glycolic acid) (PLGA), a 




first characterized the sizes of PLGA-based NP in iso-osmolar and hyperosmolar saline 
solutions. Uncoated PLGA NP were 80 nm upon formulation, but were highly unstable 
and rapidly aggregated in 3% saline (Table 7.3). On the other hand, non-adhesive PLGA-
PEG NP were 71 nm in diameter following formulation and remained stable in higher 
saline concentrations. Following in vivo CED administration, fluorescence based 
quantification of NP distribution yielded a statistically significant improvement in the 
distribution of PLGA-PEG NP as compared to its PLGA counterpart in both 0.9% saline 
and 3% saline (Figure 7.6A, B). Additionally, Vd of PLGA-PEG when administered in 
3% saline was 2.7-fold than the Vd of PLGA-PEG administered in 0.9% saline (Figure 
7.6C). Extensive PLGA-PEG distribution throughout the brain interstitium led to 
perivascular distribution along lateral striate arteries whereas unmodified PLGA NP 
remained localized to the point of administration (Figure 7.6D, E). In good agreement 
with our observations with probe particles (Figure 7.5D), we found that PLGA-PEG NP 
could escape PVS when administered in hyperosmolar 3% saline (Figure 7.6F). At a 
distance of 20 m from the blood vessel, 52% and 12% of PLGA-PEG fluorescence was 
detected when administered in 3% saline and 0.9% saline, respectively (Figure 7.6F). 
Furthermore, the percent coverage of PLGA-PEG within the brain ICS following 
administration in 3% saline was significantly higher than PLGA-PEG administered in 
0.9% saline (Figure 7.6G, P < 0.05). These results validate our findings with probe NP 
that the combined use of non-adhesive surface coatings and hyperosmolar infusate 
solution will maximize the distribution of NP as well as their drug payloads following 




biodegradable NP using an appropriate hyperosmolar infusate solution may enhance 
therapeutic distribution and further improve therapeutic efficacy. 
 
7.4. Conclusion 
We have developed a delivery strategy that focuses on maximizing NP distribution in the 
brain. We overcome the hindrances of brain ECM components and preferable NP 
trafficking and sequestration within PVS by administering non-adhesive NP using CED 
in a hyperosmolar infusate solution. In doing so, this strategy addresses the major 
drawbacks currently associated with CED in both the preclinical and clinical settings for 
treatment of neurological diseases. The results of this mechanistic study provide an 
essential level of understanding for overcoming the hindrances of the brain ECM and NP 
accumulation in PVS, both of which must be carefully considered for CED of NP 
therapeutics as well as alternative CNS administration methods including systemic, 
intranasal or intrathecal delivery routes. We anticipate incorporating this delivery strategy 
with our developed nanoparticle systems including PLGA-PEG (Chapter 4), DNA-NP 







  Table 7.1: Sizes of PSPEG and PSCOOH nanoparticles hypotonic, isotonic, or hypertonic 






Figure 7.1: H&E images of rodent brains following administration of infusate solutions. 
Animals were sacrificed either 1 hour or 72 hours post-administration. Scale bar = 50um. No 
significant cellular toxicity or inflammation was observed in the vicinity of the implanted catheter 
at either timepoint indicating limited acute or chronic toxicities. All animals exhibited normal 




Figure 7.2: Characterization of nanoparticle diffusivity ex vivo and 
distribution in vivo. (A) Mean squared displacement of PS-PEG nanoparticles in 
rodent brain slices treated with varying solutions. N>100 nanoparticles tracked 
per sample, N=4 rodent samples. * P<0.05 denotes statistical significance. (B) 
Representative coronal slices depicting the injection site of PS-PEG (red) and PS-
COOH (green) nanoparticles within rodent striatum. Yellow represents 
nanoparticle overlay. Scale bar = 1 mm. (C) Nanoparticle volume of distribution 
determined using image based MATLAB quantification methods. Statistical 
significance: * P <0.05 denoting statistical significance. (D) H&E images of 
rodent brains following administration of infusate solutions. Animals were 






Figure 7.3: Nanoparticle diffusivity ex vivo and distribution in vivo in mannitol. (A) 
Mean squared displacement of PS-PEG nanoparticles in rodent brain slices treated with 
mannitol solutions. N>100 nanoparticles tracked per sample, N=4 rodent samples. (B) 
Representative coronal slices depicting the injection site of PS-PEG (red) and PS-COOH 
(green) nanoparticles within rodent striatum. Yellow represents nanoparticle overlay. 
Scale bar = 1 mm. (C) Nanoparticle volume of distribution determined using image based 
MATLAB quantification methods. Statistical significance: * P <0.05 denoting statistical 




Figure 7.4: Nanoparticle-blood vessel association. Localization of PS-PEG (red) and PS-COOH 
(green) nanoparticles with collagen IV (white) stained blood vessels in the rodent brain is highly 
dependent on the tonicity of the solution the nanoparticles are infused in. Red and green arrows 
designates vessel of interest with PS-PEG and PS-COOH nanoparticles in the associated perivascular 
space, respectively. (A-D) Infusion in hypotonic water solution confines both nanoparticle types 
within perivascular spaces at all distances from the coronal plane of injection. (E, F, G) Up to 1.0 mm 
from the plane of injection, coinjection of nanoparticles in normal saline results in widespread 
distribution of PS-PEG in the parenchyma whereas the majority of PS-COOH line blood vessels. (H) 
At 1.5 mm, fewer PS-PEG nanoparticles are present and are mostly vessel-associated. (J-M) 
Following administration in hypertonic 3% saline, PS-PEG resides within the healthy tissue 
parenchyma up to 1.5 mm away from the plane of administration. PS-COOH distribution only 
extends out to 0.5 mm beyond the plane of injection with the majority associated with blood vessels. 







Table 7.2: Nanoparticle presence in perivascular or intercellular spaces. High resolution 
images from N=3 mice (Total of N ≥ 10 images) were analyzed for presence of PS-COOH and 
PS-PEG in PVS and ICS at specific distances from the plane of administration. Shaded boxes 
with “++” indicate that 90-100% of images depict the presence of NP. Shaded boxes with “+” 
indicate that NP were present in 80-89% of all images. Shaded boxes indicate presence of NP in 





Figure 7.5: Perivascular distribution of nanoparticles following CED. (A) Presence of PS-PEG 
(red) and PS-COOH (green) nanoparticles one hour post-infusion into the striatum using CED. White 
arrow indicates direction of injection. Fluorescent nanoparticles were imaged in the striate arteries 
following administration in (B) 3% saline, (C) 0.9% saline, and (D) water. Blue = DAPI. Overlay of 
particles represented as yellow. Scale bar (A) = 1mm. Scale bar (B, C, D) = 50 um. (E) Presence of 
fluorescence corresponding to PS-PEG nanoparticles is seen up to 100um away from the perivascular 
space of the striate artery when delivered in hypertonic 3% saline solution. PS-COOH nanoparticles do 
not effectively escape from perivascular spaces regardless of tonicity of administration vehicle. At least 
N=3 striate vessels quantified for each condition. (F) Percent coverage of PS-PEG and PS-COOH 






Table 7.3: Sizes of PLGA and PLGA-PEG nanoparticles in isotonic, or hypertonic saline 





Figure 7.6: In vivo distribution of therapeutic PLGA nanoparticles in mouse striatum administered 
via CED. (A, B) Representative coronally sliced images of PLGA-PEG (red) and PLGA (green) 
nanoparticles infused in 0.9% saline and 3% saline. Data represent the average of N ≥ 3 mouse brain 
specimen for each solution. (C) Quantified PLGA-PEG and PLGA volume of distributions in rodent 
striatum. Inset depicts the Vd of PLGA based nanoparticles. *P < 0.05 denotes statistical significance.  
(D, E) High magnification of lateral striate arteries and PLGA-PEG nanoparticles following infusion in 
(D) 0.9% saline or (E) 3% saline. (F) Percent coverage of PLGA-PEG nanoparticles in varying saline 
solutions calculated using image based MATLAB quantification. *P < 0.05 denotes statistical 
significance. G) Improved perivascular escape of PLGA-PEG nanoparticles occurs when administered in 
3% saline as opposed to 0.9% saline. Note: Parts of Figure 7.6A and 7.6C are reproduced from earlier 
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